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Summary 
Tuberculosis (TB) and the Acquired Immunodeficiency Syndrome (AIDS) are the two leading 
deadly infectious diseases globally, and in combination represent a public health problem of 
particular complexity. Though highly different in history and pathogenesis (AIDS is a viral 
infection, while TB is caused by the bacterium M. tuberculosis; AIDS is recently emerging and 
TB very ancient) the two diseases exert considerable mutual interactions that require 
specific public health measures and targeted research initiatives. The aim of this thesis was 
to provide an overview of the epidemiology of TB and HIV/M. tuberculosis co-infection and 
current diagnostic standards in Europe, identify priority areas for future research activities, 
and communicate the results to relevant stakeholders. 
To prepare an evidence-base for research priority setting, data collected by the World 
Health Organization (WHO) and the European Centre for Disease Prevention and Care 
(ECDC) were combined to a comprehensive overview of the epidemiology of TB, drug-
resistant TB, and co-infection with HIV in all 27 EU member states. This data collection was 
complemented by an assessment of diagnostic standards, looking both at the suitability of 
different test methods to actually diagnose active TB or latent infection, and at the 
availability and frequency of use of the respective tests. Modern blood-based Interferon--
release-assays (IGRAs) have been recently established as a more specific alternative to the 
classical tuberculin skin test (TST) for the diagnosis of latent TB infection, while their value 
for the diagnosis of active TB was unclear. This question was addressed in a systematic 
review and meta-analysis, and information on current clinical practice in Europe and non-
European high burden areas was collected via an electronic survey. 
Following the baseline assessment, research priorities were identified in an international 
collaborative effort. This thesis summarizes the outcomes of a consensus procedure to 
identify research needs in the area of HIV/M. tuberculosis co-infection which was performed 
by experts from Europe and the high burden areas India, Russia, Latin America, and Sub-
Saharan Africa. In an interdisciplinary and intersectoral approach, concrete suggestions for 
initiatives were defined and recommended to the European Commission. A funding analysis 
was performed to identify current funding gaps and to ensure that the suggestions for new 
initiatives were complementary to ongoing activities. Finally, to inform decision makers, 
raise further awareness for the issue of HIV/M. tuberculosis co-infection and advocate for 
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increased funding specifically for this area of research, a short film was produced which 
explains the severity of the problem, emphasizes the urgency of further research, and 
highlights the suggested focus topics. 
Results and conclusions 
The epidemiological overview illustrates that TB surveillance data in Europe are incomplete, 
and particularly scarce for co-infection with HIV. Those data that were available revealed a 
diverse distribution pattern with both high and low prevalence countries among the 27 
member states, and hotspots scattered throughout. This suggests that generalized 
approaches for the whole of Europe may be oversimplistic, and emphasizes the need of 
improved disease monitoring to allow targeted planning of effective control measures and 
new research initiatives. 
Diagnostic standards in Europe on the other hand are high, especially in comparison to most 
high prevalence regions, as confirmed by the results of the electronic survey. According to 
the collected information, IGRAs are widely available and routinely applied in most European 
countries. Their sensitivity is higher than that of the TST but not sufficient to recommend 
them as a single rule out test for active TB, as the meta-analysis data suggest. Also, 
specificity is too low to distinguish active disease from latent infection. These results have 
already been taken up in ECDC guidelines for the use of IGRAs, which may contribute to a 
further improvement and harmonization of diagnostic standards in Europe. The meta-
analysis furthermore showed that, when applied to extransanguinous fluids, the T-SPOT.TB 
assay seems to be the best commercially available immunodiagnostic test to detect active 
TB, but more independent and carefully designed prospective studies are needed to confirm 
these results. 
This is in line with the results of the consensus procedure which identified diagnostics as one 
of the main areas of interest, along with specific questions in basic research, clinical sciences, 
training and networking. While several of these recommendations have already been 
reflected in the latest EU calls, co-infection remains a clear gap and needs increased support. 
The produced short film has proven as a highly useful means to advocate for such funding on 
local, national and global level. 
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Zusammenfassung 
Tuberkulose und AIDS sind die beiden tödlichsten Infektionskrankheiten weltweit und stellen 
in ihrer Kombination ein besonders komplexes Problem für das globale Gesundheitswesen 
dar. Die vielfältigen Wechselwirkungen der beiden Erkrankungen erfordern spezifische 
Kontrollmaßnahmen und gezielte Forschungsinitiativen. Ziel dieser Arbeit war es, einen 
Überblick über die Epidemiologie der TB und der Ko-Infektion mit HIV sowie über 
diagnostische Standards in Europa zu geben, auf dessen Basis Forschungsprioritäten zu 
definieren, und diese an relevante Interessensgruppen zu kommunizieren. 
Als Grundlage für die evidenzbasierte Definition von Forschungsprioritäten wurde mit Hilfe 
von Daten der Weltgesundheitsorganisation (WHO) und des Europäischen Zentrums für die 
Prävention und die Kontrolle von Krankheiten (ECDC) ein umfassender und detaillierter 
Überblick über die Epidemiologie der TB, der resistenten TB und der Ko-Infektion mit HIV in 
allen 27 EU Mitgliedsstaaten zusammengestellt. Dieser wurde um Informationen zu 
diagnostischen Standards in der klinischen Praxis ergänzt. In den letzten Jahren haben sich 
IGRAs, immundiagnostische Bluttests, als Alternative zum klassische intrakutanen 
Tuberkulin-Hauttest für die spezifische Diagnose einer latenten Tuberkuloseinfektion 
etabliert. Ihre Eignung zum Nachweis der aktiven TB war jedoch unklar und wurde daher im 
Rahmen einer systematischen Metaanalyse untersucht. Zusätzlich wurden in einer 
elektronischen Umfrage Daten zur Verfügbarkeit und zur Häufigkeit der Anwendung der 
jeweiligen Tests in Europa und in den am meisten durch diese Erkrankungen betroffenen 
Regionen der Welt erhoben. 
Darauf basierend wurden unter Beteiligung von Experten aus Europa und den 
Hochprävalenzregionen Indien, Russland, Lateinamerika und Subäquatorialafrika 
Forschungsprioritäten im Bereich HIV/M. tuberculosis Ko-Infektion definiert, die in der 
vorliegenden Arbeit zusammengefasst sind. In einem interdisziplinären, 
sektorübergreifenden Ansatz wurden konkrete Vorschläge für zukünftige Initiativen 
erarbeitet und als Empfehlungen an die Europäische Kommission weitergegeben. Mit Hilfe 
einer Fördermittelanalyse wurde die europäische Forschungslandschaft hinsichtlich 
Finanzierungslücken untersucht um sicherzustellen, dass die erarbeiteten Vorschläge 
komplementär zu bestehenden Initiativen sind. Um Entscheidungsträger gezielt zu 
informieren, wurde ein Kurzfilm produziert, der die Komplexität des Problems vermittelt und 
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die Notwendigkeit weiterer Forschungsarbeiten im Bereich der HIV/M. tuberculosis Ko-
Infektion erläutert. 
Ergebnisse und Schlussfolgerungen 
Der epidemiologische Überblick macht deutlich, dass Datenerfassung in Europa 
insbesondere zur Ko-Infektion mit HIV unvollständig ist. Es zeigt sich ein unregelmäßiges 
Verteilungsmuster von Hoch-und Niedrigprävalenzländern sowie vereinzelten 
Brennpunkten. Dies legt nahe, dass generalisierte Ansätze für Europa als Ganzes zu 
unspezifisch sind, und unterstreicht die Notwendigkeit einer verbesserten 
Krankheitsüberwachung als Basis für gezielte Planungen effektiver Kontrollmaßnahmen und 
neuer Forschungsinitiativen. 
Die diagnostischen Standards innerhalb der EU sind dagegen hoch, insbesondere im 
Vergleich zu den untersuchten Hochprävalenzgebieten. Die elektronische Umfrage belegt, 
dass IGRAs in den meisten der 27 EU-Mitgliedsstaaten verfügbar und Teil der klinischen 
Routine sind. Die Metaanalyse zeigt, dass ihre Sensitivität die des klassischen intrakutanen 
Tuberkulin-Hauttests übertrifft, jedoch nicht hoch genug ist, um sie als alleinigen Test für 
den Ausschluss aktiver TB zu empfehlen. Darüber hinaus bestätigt die Analyse, dass die 
Spezifität der IGRAs nicht ausreicht, um zwischen aktiver und latenter TB zu differenzieren. 
Diese Resultate sind bereits in die Erstellung europäischer Richtlinien zur Nutzung von IGRAs 
eingeflossen. Weiterhin legen die Daten nahe, dass der T-SPOT.TB Assay der beste 
kommerziell verfügbare immundiagnostische Test für den Nachweis einer aktiven TB durch 
die Untersuchung extransanguiner Körperflüssigkeiten zu sein scheint. Diese Ergebnisse sind 
jedoch in zusätzlichen, unabhängigen prospektiven Studien zu bestätigen. 
Neben der Diagnostik wurden unter Beteiligung des internationalen Expertengremium auch 
spezifische Fragestellungen im Bereich der Grundlagenforschung und der klinischen 
Forschung als Prioritäten erarbeitet und festgelegt, sowie auf die Bedeutung von gezielter 
Aus- und Weiterbildung im Bereich der HIV/M. tuberculosis Ko-Infektion hingewiesen. 
Während einige der Empfehlungen in den jüngsten Ausschreibungsrunden der EU-
Kommission bereits umgesetzt wurden, bleibt im Bereich der HIV/M. tuberculosis Ko-
Infektion ein klarer Bedarf für weitere Forschungsinitiativen bestehen. Der produzierte 
Kurzfilm hat sich als probates Mittel erwiesen, um auf regionaler, nationaler und globaler 
Ebene für weitere Fördermittel zu werben. 
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1 Introduction 
Tuberculosis (TB) has plagued mankind for thousands of years and, though curable in 
principle, remains the most deadly infectious disease, with the estimated total number of 
incident cases of TB worldwide rising to 9.4 million in 2009 - more than at any other time in 
history (WORLD HEALTH ORGANIZATION, 2003; HERSHKOVITZ, 2008; LAWN, ZUMLA, 2011; 
WORLD HEALTH ORGANIZATION, 2011b). The infectious agent causing the disease, 
Mycobacterium tuberculosis (MTB), is responsible for more human deaths than any other 
single pathogen today (OTTENHOFF, KAUFMANN, 2012). Especially co-infection with the 
human immunodeficiency virus (HIV) has led to a major upsurge again and boosts the 
development and spread of drug resistant strains, which are currently posing a serious 
challenge particularly in Europe (WELLS et al., 2007; GANDHI et al., 2010). 
1.1 The history of tuberculosis in Europe 
The oldest evidence for MTB infection in humans so far was discovered in 2008 in human 
remains from 9,000 years ago in a settlement in the eastern Mediterranean (HERSHKOVITZ, 
2008). As one of the earliest medical documentations, Hippocrates in 400 BC described 
phtisis as the most common cause of illness of his times, stating that the disease was 
affecting primarily young people between 18 and 35 of age, with a fatal outcome in the vast 
majority of cases (HIPPOCRATES, 400 BC). 
A massive TB epidemic in Europe, known as the Great White Plague, started in the 17th 
century, and lasted for over 200 years. In peak times, TB case rates in London had reached 
1,000 per 100,000 population per year, making it the principal cause of death by 1650. Once 
an individual was diagnosed with TB, death was considered inevitable. The high population 
density as well as poor sanitary conditions created an environment in which the disease 
could perfectly flourish. In the early 19th century, TB, often also referred to as Consumption, 
still accounted for up to 25% of deaths in Europe (LAWN, ZUMLA, 2011) but was now 
regarded as a ‘romantic’ disease and popularized as the disease of artists, with Frédéric 
Chopin, Paul Gauguin or Honoré de Balzac being just a few of many famous examples of the 
time. 
The first to discover the pathogen causing TB was the German scientist and later Nobel 
Laureate Robert Koch, who presented his finding on March 24, 1882 at the Physiological 
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Society of Berlin. This day has since been known as World TB Day. Koch published his 
findings shortly afterwards, for the first time establishing a direct relationship between a 
causative microbe and an infectious disease. In his article entitled ‘Die Ätiologie der 
Tuberkulose’, Koch demonstrated that the bacterium he had identified was the single 
causative agent for all known forms of TB (KOCH, 1884). 
In 1895, Wilhelm Roentgen discovered the X-ray, providing the first reliable tool for 
diagnosis and monitoring of disease progression. A few years later in 1908, tuberculin, a 
purified protein derivative (PPD) of the bacteria developed by Koch in 1890 - originally in 
search for an effective means of immunization - was shown by Felix Mendel and Charles 
Mantoux to be an effective intradermal test for diagnosing TB. The Mantoux test or 
Tuberculin Skin Test (TST) is still standard diagnostic practice throughout the world today 
(LANGE, SESTER, 2012). 
With improving living standards (hygiene, better nutrition, improved housing conditions) 
early in the 20th century, the death toll from TB finally began to fall. Bacillus Calmette-Guérin 
(BCG) was described as a TB vaccine by Albert Calmette, director of the Institut Pasteur in 
Lille, and his colleague Camille Guérin in 1906, and entered into clinics in 1921. In 1943, the 
first antibiotic, streptomycin, was discovered by Albert Schatz, Elizabeth Bugie, and Selman 
Waksman in the US, and described as the first effective anti-TB drug a year later. Thus, by 
the second half of the 20th century, human TB was considered controllable, and its 
elimination just a matter of time (KESHAVJEE, FARMER, 2012). 
Consequently, research and development (R&D) activities began to fade in the second half of 
the 19th century. As TB is a chronic disease, control failures do not become apparent 
immediately, though, but surface only much later (KAUFMANN, PARIDA, 2007). Today, 
significant setbacks clearly show that both scientists and clinicians had been falsely satisfied 
with the early achievements: i) BCG, still the only approved vaccine against TB to date, 
turned out to be not sufficiently effective. Despite the relative efficacy of BCG in infants, it 
fails to prevent pulmonary TB in adolescents (OTTENHOFF, KAUFMANN, 2012); ii) 
Development of (multi-) resistance against anti TB-drugs, as seen already in the early days of 
TB chemotherapy, has been massively increasing in the last years (NACHEGA, CHAISSON, 
2003); iii) The global AIDS pandemic has caused an explosive increase in TB incidence 
(CORBETT et al., 2003; WELLS et al., 2007). 
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Consequently, TB is escalating again, and some aspects hit Europe particularly hard. 
According to estimates of the World Health Organization (WHO), two billion people are 
infected with MTB globally, i.e. one third of the world’s population, representing an 
immense reservoir of the infectious agent. Thus, intensified efforts and concerted action are 
needed to tackle the global threat. 
1.2 The pathogen 
MTB is an intracellular pathogen that can infect several animal species, but human beings 
are the principal hosts. The straight or slightly curved MTB rods are ranging in size from 0.3 
to 0.6 by 0.5 to 4.0 micrometers, occurring singly and in occasional threads (Figure 1). MTB is 
an aerobic, acid-fast and acid-alcohol-fast, gram-positive, non-motile, non-encapsulated 
bacillus which grows most successfully in tissues with high oxygen content such as the lungs. 
Even under ideal conditions, however, growth is extremely slow. MTB divides every 15 - 20h, 
while other bacteria usually divide in less than one hour (e.g. E. coli every 20 minutes) 
(WAYNE, KUBICA, 1986). This slow replication rate of MTB results in a particularly long time 
of several weeks to diagnosis in culture, and is also causal for the need of an unusually long 
duration of drug therapy, both for the treatment of disease as well as for preventive 
chemotherapy. 
Figure 1. Mycobacterium tuberculosis. Source: CDC, 2011. 
The bacterium belongs to the Mycobacterium Tuberculosis Complex (MTC), which groups 
mycobacteria that cause human and/or animal TB (as opposed to non-tuberculous 
mycobacteria, NTM) and is comprised of the classical species M. tuberculosis, M. africanum, 
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M. microti, and M. bovis (BROSCH et al., 2002), as well as newer additions M. caprae 
(ARANAZ et al., 2003), M. pinnipedii (COUSINS et al., 2003), and M. canetti (VAN SOOLINGEN 
et al., 1997). 
M. africanum is globally not widespread, but it represents up to 60% of clinical strains from 
patients with pulmonary TB, particularly in Western African countries (NIEMANN et al., 
2004). M. microti causes TB mainly in small rodents like voles, and only few cases of 
infections in humans have been described (XAVIER EMMANUEL et al., 2007). M. bovis can 
cause TB in various domestic or wild animals like cattle or goats (WAYNE, KUBICA, 1986), but 
can also infect humans via milk products. The introduction of pasteurization, however, has 
largely eliminated TB caused by M. bovis as a public health problem in humans (NIEMANN et 
al., 2000). M. caprae has been isolated from cattle, wild boar and pigs in different European 
countries (ARANAZ et al., 2003) and was recently shown to cause tuberculous meningitis 
also in humans (HANSEN et al., 2012), while M. pinipedii seems to be restricted to seals 
(COUSINS et al., 2003). M. canetti has been isolated from single human patients but seems 
very rare (VAN SOOLINGEN et al., 1997). 
1.3 Transmission, infection, and immune response 
TB may be the only communicable disease with obligate airborne transmission (ROY, 
MILTON, 2004). The pathogen is transmitted by aerosols which are produced by individuals 
with active TB. Infectious bacilli can be aerosolized by any respiratory manoeuvre, i.e. 
talking, singing, coughing, or sneezing. The larger the physical force, the higher the number 
of exhaled droplets and the smaller their size, and the quicker the tubercle bacilli evaporate 
into droplet nuclei - a form in which they can remain airborne for several hours. 
Transmission occurs when a new host inhales MTB, and the bacilli reach the alveoli of the 
lungs. Estimates of the minimum infectious dose range from a single bacterium upward, and 
the risk of infection is closely linked with time and frequency of exposure as well as age and 
immune status of the exposed individual (ERKENS et al., 2010; RUSSELL et al., 2010; 
OTTENHOFF, KAUFMANN, 2012). Uptake of MTB can result in different clinical outcomes, 
ranging from the complete absence of clinical or laboratory evidence of infection, to 
detectable infection with no signs of clinically active disease, to active TB (WALZL et al., 
2011). The disease most commonly affects the lungs (‘pulmonary TB’) but can occur in 
almost any anatomical site or as disseminated disease. 
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The actual outcome of exposure depends on the ability of the host’s innate and adaptive 
immune system to eradicate or control the bacterium. After inhalation into the lungs of a 
new host, the bacilli are phagocytosed by various cell types, including alveolar macrophages, 
interstitial macrophages, local dendritic cells, and likely also epithelial cells, as part of the 
innate immune system (OTTENHOFF, KAUFMANN, 2012). As part of adaptive immunity, CD4+ 
T-cells secrete interferon-IFN- and tumor necrosis factor-α (TNF-α), which activate 
macrophages to destroy ingested mycobacteria (FLYNN et al., 1993). However, the onset of 
adaptive immune response mechanisms is delayed by several weeks after infection with 
MTB as compared to other infections (URDAHL et al., 2011). During that initial phase of 
uninhibited exponential replication, two types of MTB populations can develop: (i) dormant 
bacilli with very low metabolic activity that do not replicate but can persist in infected cells 
over very long periods of time, presenting a potential reservoir of bacteria that can 
resuscitate later; and (ii) actively replicating bacteria (OTTENHOFF, KAUFMANN, 2012). 
1.4 Latency  
For immunocompetent individuals, the annual risk of developing active clinical TB after 
inhalation of viable MTB bacteria is relatively low and decreases over time, with an 
estimated lifetime risk of about 10% (DYE, WILLIAMS, 2010). In turn, this means that in over 
90% of infected individuals, the immune system can either eliminate the bacilli, or keep the 
infection sufficiently under control. Such a quiescent infection is often referred to as ‘latent 
tuberculosis infection’ (LTBI), and typically comes along with evidence of T-cell priming (VAN 
SOOLINGEN et al., 1997). 
After an initial phase of bacterial growth, activated macrophages are able to sustain bacterial 
load at a relatively constant level. The infection passes over to a state of chronicity, with 
bacteria persisting enclosed in granulomas. Initially they are surrounded by an amorphous 
accumulation of macrophages, monocytes, and neutrophils. With the development of an 
acquired immune response and the recruitment of MTB-specific lymphocytes about 2 to 3 
weeks after infection, the granuloma develops a stratified structure and the caseous core of 
the granuloma becomes hypoxic – a condition which in culture has been shown to induce 
non-replicative persistence of MTB (RUSSELL et al., 2010). 
LTBI is symptom-free, and infected individuals are not contagious. They may carry viable 
MTB for years and decades without ever developing any signs of disease, or showing 
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macroscopic or histological evidence of TB (HERNANDEZ-PANDO et al., 2000). However, 
granulomas are not fixed inert structures; cells are constantly dying and replaced by new 
cells, and debris is being removed. If the immunological balance is disturbed, however, 
active replication may start again and can lead to subclinical or even clinically active 
infection (VAN SOOLINGEN et al., 1997; BARRY et al., 2009; MACK et al., 2009). In this stage, 
patients re-establish infectiousness and - as long as untreated - will spread the infection on 
average to 10 to 15 new people per year (WORLD HEALTH ORGANIZATION, 2002), i.e. 
roughly one person per month. 
While the traditional separation between active disease and latent infection as two distinct 
binary states works well in clinical and public health contexts, it is recognized that this model 
does not provide a sound basis for immunologic studies (ERNST et al., 2012). Latest evidence 
suggests that LTBI likely includes a much broader spectrum of states, ranging from complete 
clearance of infection to subclinical active disease, and that a continuous spectrum of these 
states exists both in the same individual and between different individuals (BARRY et al., 
2009; LAWN et al., 2011; LAWN, ZUMLA, 2011; WALZL et al., 2011). 
1.5 TB diagnostics 
In addition to the evaluation of a patient’s medical history, clinical symptoms and chest X-
ray, active TB is diagnosed by the detection of the pathogen. The most commonly used 
diagnostic test for TB globally, sputum smear microscopy through staining of acid-fast bacilli 
(AFB) as described by Robert Koch, is 125 years old and routinely misses 50% of all cases. In 
fact, only 44% of all new adult cases and 15-20% of childhood cases are identified by the 
presence of AFB in sputum smears (NEWTON et al., 2008; WORLD HEALTH ORGANIZATION, 
2009). 
The gold standard for the definite diagnosis of active TB is therefore still the detection of 
MTB by culture methods, which takes several weeks due to the slow replication rate of the 
pathogen. Furthermore, MTB culture requires a laboratory infrastructure that is not widely 
available in resource poor settings hence cannot be used nationwide in many of the high 
burden countries. 
Two diagnostic methods are currently in use to support the diagnosis of LTBI: the tuberculin 
skin test (TST) and in vitro interferon- release assays (IGRAs). Both tests are immunological 
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methods that measure specific acquired immune responses (MACK et al., 2009; YOUNG et 
al., 2009), and are thus an indirect marker for past or current infection. 
For the Tuberculin skin test (TST), a standard dose of tuberculin-purified protein derivative 
(PPD) is injected intradermally into the volar surface of the forearm and is read 48 to 72 
hours later. The immune response is assessed by measuring the diameter of induration in 
millimeters. Depending on specific risk factors, an induration of 5mm, 10mm, or 15mm 
represent a positive result (MACK et al., 2009). However, the test has several shortcomings. 
Besides the difficulty of standardized read-outs, it is disadvantageous that patients must 
return to their health-care provider to have their test evaluated. Also, contact with NTM or 
BCG vaccination can lead to false-positive TST results, as the PPD contains antigens which 
are also present in BCG and certain NTM. 
In recent years, blood-based in vitro interferon- release assays (IGRAs) have been 
developed as alternatives to the TST. IGRAs are more specific than the TST, as they are based 
on the in vitro stimulation of peripheral blood T-cells which are specific for the MTB specific 
antigens early secretory antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) 
(ANDERSEN et al., 2000), i.e. false-positive results from contact with NTM or BCG vaccination 
can be avoided. The presence of reactive T-cells is assessed by the induction of interferon- 
(IFN-). Two IGRAs are currently commercially available: The QuantiFERON®-TB Gold in-tube 
assay (QFT-GIT) produced by Cellestis, an Australian company which was recently acquired 
by Qiagen, Germany, and the T-Spot®.TB assay, which was developed by the University of 
Oxford and is now produced and distributed by Oxford Immunotec Ltd., UK. 
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The QuantiFERON®-TB Gold in-tube test uses the enzyme-linked immunosorbent assay 
(ELISA) detection method. The assay consists of 3 blood collection tubes (nil, TB antigens 
ESAT-6, CFP-10 and TB7.7 dried to the wall of the tubes, and mitogen (phyto-hæmagglutinin, 
PHA) (Figure 2). IFN- is measured from the supernatants of whole blood after a stimulation 
time of 16-24 hours. Results are interpreted qualitatively as negative, positive or 
indeterminate according to the manufacturer’s recommendations (Table 1). 
 
 
 
 
Figure 2. QuantiFERON
®
-TB Gold in-tube blood collection tubes. 
 
Table 1. Interpretation criteria for the QuantiFERON-TB Gold In-Tube assay (QFT-GIT). 
 
 result 
IFN-γ concentration (International Units per ml, IU/ml) 
MTB antigens nil PHA nil 
positive ≥ 0.35 IU/ml and ≥ 25% over nil ≤ 8.0 IU/ml any 
negative < 0.35 IU/ml or < 25% over nil ≤ 8.0 IU/ml ≥ 0.5 IU/ml 
indeterminate <0.35 IU/ml or < 25% over nil ≤ 8.0 IU/ml < 0.5 IU/ml 
 any > 8.0 IU/ml any 
 
For the T-Spot®.TB test, which is based on the enzyme-linked immunosorbent spot (ELISPOT) 
assay, peripheral blood mononuclear cells (PBMC) are isolated through density gradient 
centrifugation, washed and counted. 250,000 PBMC are added to wells that are pre-coated 
with IFN- antibodies and stimulated for 16-20 hours by ESAT-6 and CFP-10 along with 
negative (nil) and positive controls (PHA). Activated T-cells release IFN- which is locally 
captured and detected by a secondary antibody to IFN-. Spots are counted (Figure 3), and 
results are qualitatively interpreted as negative, positive or indeterminate according to the 
manufacturer’s recommendations (Table 2). 
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Figure 3. Principle of the T-Spot®.TB assay system. Source: www.oxfordimmunotec.com. 
 
Table 2. Interpretation criteria for the T-Spot®.TB assay. 
 
 result 
spot count 
MTB antigens nil PHA 
ESAT-6  CFP-10   
positive ≥ 6 over nil and/or ≥ 6 over nil ≤ 10 any 
negative ≤ 5 over nil and/or ≤ 5 over nil ≤ 10 ≥ 20 
indeterminate ≤ 6 over nil and ≤ 6 over nil ≤ 10 < 20 
 any  any > 10 any 
 
As this assay controls for overall numbers of PMBCs in an individual stimulatory reaction, the 
T-Spot.TB test is less susceptible to a loss of CD4+ T-cells as caused e.g. by HIV infection and 
has thus been recommended as the preferred option for diagnosis of LTBI in HIV/MTB co-
infected individuals (LEIDL et al., 2010). 
The increase in specificity as compared to skin testing has raised some hope that IGRAs may 
have potential to be used in the diagnosis of active TB. Although individual studies have 
provided evidence that neither the TST nor IGRAs can discriminate between active and 
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latent infection (MACK et al., 2009), this has not been formally assessed in larger systematic 
reviews and meta-analyses. In addition, a systematic review of studies on the use of IGRAs 
from extrasanguinous fluids had not yet been performed.  
1.6 Emerging drug resistance 
Though the first antibiotic and thus the first effective treatment against TB was discovered 
as early as in 1944, treatment of TB has recently been confronted with severe setbacks. The 
past two decades were marked by a worldwide emergence of multi drug resistant (MDR) 
tuberculosis, then extensively resistant (XDR) TB, and, most recently, strains that are 
resistant to all anti-TB drugs (MIGLIORI et al., 2007; SHAH et al., 2007; GANDHI et al., 2010). 
TB drug resistance can either be the result of primary infection with a resistant strain, or 
develop during treatment. Resistance of a primarily susceptible bacillus can be caused by a 
point mutation, or by a nucleotide deletion or insertion. Under normal conditions the 
mutant organisms are by far outnumbered by drug-susceptible bacilli. In the presence of an 
antimicrobial agent, however, susceptible organisms are reduced in number, which leads to 
a selective pressure in favor of the mutant organism. A TB patient who is treated with one 
single antibiotic drug will experience an initial response to treatment, but resistant bacteria 
can continue to replicate in the presence of the drug and can become predominant, 
resulting in a recurrence of the disease which is then fully resistant to the drug (NACHEGA, 
CHAISSON, 2003). Mutations for resistance to isoniazid, rifampicin, ethambutol or 
streptomycin are however very infrequent in MTB (estimated prevalence of mutation of 1 in 
106 - 108 bacilli), and the probability of random mutations in an individual bacillus resulting 
in resistance to more than one drug consequently is extremely low. Standard treatment 
therefore consists of at least two, mostly three different antibiotics, so that any single 
pathogen that develops resistance to one of the drugs is at the same time confronted with at 
least one other antibiotic to which it should be susceptible. However, experience has shown 
that failure of local health-care systems in high burden settings can quickly lead to a 
systematic selection and spread of lethal multi or extensively drug-resistant strains (RUSSELL 
et al., 2010). 
MDR-TB is defined as resistance to at least the two first-line drugs (isoniazid and rifampicin), 
while XDR-TB is caused by bacteria that in addition are resistant to any fluoroquinolone and 
at least one of three injectable second-line drugs (i.e. amikacin, kanamycin, or capreomycin). 
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It is estimated that there were about 0.5 million incident cases of MDR tuberculosis and 
50,000 cases of XDR-TB in 2007. Among the MDR cases, about 0.3 million were new cases, 
i.e. showing primary drug resistance, and 0.2 million were patients previously treated for 
tuberculosis, i.e. with drug resistance acquired during previous treatment (WORLD HEALTH 
ORGANIZATION, 2011b). The latest WHO estimates suggest that globally and in the region of 
the Americas, levels of MDR-TB among new TB patients are relatively stable, and that 
numbers are falling in the Eastern Mediterranean, South-East Asia and Western Pacific 
regions while increasing in Africa and the European Region (WORLD HEALTH 
ORGANIZATION, 2011b). 
Nevertheless, numbers were only reported as summary values for the WHO European 
Region and selected hot spot countries in that region. A detailed overview of the situation in 
the 27 member states of the European Union (EU27) was not available and should thus be 
compiled. 
1.7 Co-infection with HIV 
HIV, the pathogen which causes the Acquired Immune Deficiency Syndrome (AIDS), was first 
described in 1983 by Luc Montagnier and Françoise Barré-Sinoussi from the Institut Pasteur 
in Paris, and its devastating effects on the global TB balance became clear shortly thereafter. 
Today, it is well recognized that AIDS and TB form a lethal combination, each boosting the 
other's progress, and that the emergence of AIDS has led to a major upsurge in TB cases and 
TB mortality again in many countries (LAWN et al., 2011; WORLD HEALTH ORGANIZATION, 
2011b). 
HIV is a retrovirus that infects CD4+ T-cells, dendritic cells, and macrophages. In addition to 
the profound functional and numeric depletion of CD4+ T-cells, it is assumed that HIV targets 
and depletes MTB antigen-specific CD4+ T lymphocytes earlier and at a greater frequency 
than CD4+ T-cells specific for other antigens (ERNST, 2012). Consequently, HIV co-infection 
directly impacts the ability of the immune system to control MTB infection (LAWN, ZUMLA, 
2011). Thus, the virus renders patients more susceptible to infection, and also increases the 
likelihood of ‘latently’ infected individuals to develop active disease through reactivation. 
Fifteen million people are estimated to be co-infected with MTB and HIV, with the risk to 
develop active TB increasing from an approximately 10% lifetime risk in immunocompetent 
20 
individuals to over 10% each year in a co-infected patient (VAN SOOLINGEN et al., 1997; 
WORLD HEALTH ORGANIZATION, 2009). 
Co-infection with HIV has a profound impact on the spectrum of TB disease, with HIV-
induced progressive immunodeficiency increasing the risk of extrapulmonary and 
disseminated disease (PHILIPS, ERNST, 2012). TB is the most common opportunistic disease 
and the leading cause of death for people infected with HIV, resulting in an increased 
morbidity and mortality of TB infection both globally and in Europe (TOOSSI, 2003). 
Furthermore, TB diagnosis is more difficult in individuals co-infected with HIV. HIV-
associated TB is more likely to be smear-negative than TB in individuals who are HIV-
negative due to a reduced inflammatory response with lower rates of cavitation in the lung 
(GETAHUN et al., 2007). Despite lower bacillary burden in sputum, the total numbers of 
mycobacteria in patients with advanced HIV infection and TB may be very high (LAWN et al., 
2011). Postmortem studies of HIV-infected patients consistently found TB to be the most 
common cause of death. In most cases, patients were affected by undiagnosed disseminated 
TB (RANA et al., 2000; ANSARI et al., 2002). These studies emphasize that HIV-associated 
disseminated TB may significantly contribute to HIV-associated mortality but frequently 
remains subclinical and undiagnosed. Thus, the WHO estimate of approximately 0.5 million 
deaths per year in patients with HIV-associated TB may even be an underestimate (LAWN et 
al., 2008). 
Tests which rely on the measurement of MTB-specific immune reactions such as the TST or 
IGRAs naturally often fail in immunocompromised patients. In some HIV/MTB endemic 
countries, this leads a situation where less than 40% of all cases are detected, thus leaving 
the majority of HIV-associated TB cases undiagnosed (MCNERNEY et al., 2012). Hence, HIV 
co-infected individuals represent a large reservoir of undetected infectious agents, are much 
more prone to conversion, and, once active TB has developed, may further spread the 
bacillus again. 
To further complicate the situation, not only the infection itself, but also a successful onset 
of anti HIV treatment can lead to TB-associated damage: When HIV and MTB co-infected 
individuals are treated with antiretroviral drugs against HIV, they are at risk of developing an 
immune reconstitution inflammatory syndrome (IRIS), where the recovery of the immune 
system leads a sudden increase in the inflammatory response, causing either non-specific 
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symptoms such as fever, or in some cases a worsening of damage to the infected tissue. In 
severe cases, this may even result in increased morbidity (MEINTJES et al., 2008). 
For all these reasons, the HIV pandemic presents a significant challenge to global TB control 
(WORLD HEALTH ORGANIZATION, 2012c), and special measures need to be taken both for 
disease control and further research. 
Despite the fact that AIDS and TB are considered poverty related diseases, this also applies 
to Europe, where TB is declining in Western and Central Europe, but still high and increasing 
in Eastern Europe. HIV/AIDS, which has been prevalent in the past in countries in Western 
Europe, is increasing dramatically in Eastern Europe, boosting the spread of TB, including 
MDR-TB and XDR-TB. In view of these developments, the WHO in 2003 announced that they 
expect a significant acceleration of morbidity and mortality attributed to HIV/MTB co-
infection in Europe in the future (WORLD HEALTH ORGANIZATION, 2003). 
Thus, an evidence-based process to identify priority research issues in this field, driven by 
Europe and realized in an international process including stakeholders from both disciplines 
and those areas in the world that are most affected by the dual infection, seemed necessary 
and timely. 
1.8 Surveillance 
Recording and reporting of data are fundamental components of patient care and disease 
control, and an important basis for research planning. Data collection and reporting are 
necessary to monitor trends in the TB epidemic at all levels (global, national, and 
subnational), and to document treatment progress. Furthermore, those data represent a 
sound basis to plan, implement and evaluate efforts for disease control and to allocate 
resources accordingly. Functioning surveillance allows an early identification of hotspots or 
new trends and developments that require particular action. When high-quality data are 
available, corrective actions can be taken where needed, and successes can be documented 
(WORLD HEALTH ORGANIZATION, 2012a). This applies both to health policy measures as 
well as to research and development (R&D) questions. In the context of TB research, it 
allows detailed description of the populations included in clinical studies and provides an 
important basis for decisions on research questions and allocation of funding. 
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The ECDC, founded in 2005, and WHO/Europe jointly coordinate TB surveillance in the WHO 
European Region (27 EU member states, 3 European Economic Area (EU/EEA) countries, and 
24 additional states, see Figure 4). Both organizations have agreed to share the data 
submitted by the 54 Member States of the WHO European Region and all tasks related to 
surveillance and monitoring of TB. For this purpose, a joint TB information system has been 
developed using a web-based common reporting entry point. TB surveillance data from the 
EU27 and EEA countries are processed through The European Surveillance System (TESSy) 
platform hosted by ECDC (established in 2008). Data from all other countries are processed 
through WHO’s Global Tuberculosis database. Submitted data are validated and exchanged 
between ECDC and WHO/Europe. 
 
 
 
 
 
 
Figure 4. EU27 in the WHO European Region. 
The 27 EU Member States (dark blue): Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the 
Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom. EEA 
(European Economic Area) countries Iceland, Liechtenstein and Norway and the 24 remaining countries in the 
WHO European Region (non-EU/EEA) (light blue): Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and 
Herzegovina, Croatia, Georgia, Israel, Kazakhstan, Kyrgyzstan, the former Yugoslav Republic of Macedonia, 
Moldova, Monaco, Montenegro, Russia, San Marino, Serbia, Switzerland, Tajikistan, Turkey, Turkmenistan, 
Ukraine and Uzbekistan. 
However, data are only published for the WHO European Region as a whole, and selected 
high burden countries within that area, but a specific and comprehensive overview of the 
epidemiological situation of the European Union was not available and thus to be compiled 
in the framework of this thesis. 
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1.9 Political and financial support 
Funding for TB research was very minor until TB was declared a global emergency in 1993. 
With increasing awareness, the first research groups were funded to translate the results of 
basic research into new applications. Today, international collaboration is a key element of 
all large funding programmes, as is increasingly also the cooperation between the academic 
and the industrial sector (KAUFMANN, PARIDA, 2007). The last two decades have been 
characterized by visible political support, an increasing effort to streamline activities, and a 
strong increase in private funding, leading also to the creation of public-private-partnerships 
(PPP), which help optimize the use of scarce resources. 
On the political level, global support was expressed in the United Nations Millennium 
Declaration in 2000, and has subsequently been confirmed on a number of occasions at 
high-level summits such as the annual G8 meetings and the Berlin declaration on TB (WORLD 
HEALTH ORGANIZATION, 2007). The Stop TB Partnership has established dedicated working 
groups for new TB diagnostics, new TB drugs, new TB vaccines, and most recently a TB/HIV 
Working Group with an Infection Control Subgroup. 
As a consequence, new public funding programmes with a clear focus on infectious diseases 
have been initiated, such as the European and Developing Countries Clinical Trials 
Partnership (EDCTP), a partnership between currently 16 European states and a large 
number of sub-Saharan African countries. The EDCTP is specifically dedicated to poverty 
related diseases (PRD) research with a clear focus on and strong participation of Sub-Saharan 
Africa and an attempt to build sustainable capacities in this endemic region. 
In recent years, private investors such as the Bill & Melinda Gates Foundation (BMGF) or the 
Global Fund for AIDS, TB and Malaria have started to significantly contribute to TB and/or 
HIV/AIDS funding. While BMGF has quickly developed to be a key player in global TB 
research funding, the Global Fund has a strong focus on HIV/AIDS, with only 15% of the total 
funding going to TB, of which again the majority is dedicated to TB control programs 
(KAUFMANN, PARIDA, 2007). 
In several successful cases, the public and private sector have joined forces and combined 
resources in newly created non-profit public private partnerships (PPP), such as the 
Foundation for Innovative New Diagnostics (FIND, 2003), which drives the development and 
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early implementation of innovative diagnostic tests for TB and other diseases, the TB 
Alliance (2000) which is dedicated to the discovery and development of new, faster-acting 
and affordable TB drugs, and Aeras (2003), a product development organization dedicated to 
the development of effective TB vaccines. 
Despite these efforts, however, the total funding available for TB research and development 
still falls short of the US$ 1.8 billion per year that is called for in the Global Plan to Stop TB 
2011–2015 (WORLD HEALTH ORGANIZATION, 2011a). With a clear shortage of funds, 
thorough monitoring of research-spending and informed evidence-based decision making 
become increasingly important. 
In order to monitor the spending of research funds, the BMGF has commissioned the 
George Institute for International Health to conduct annual surveys of global investment into 
R&D of new pharmaceutical products to prevent, manage, or cure diseases of the developing 
world (MORAN et al., 2009a). This G-FINDER survey is intended to report accurate, 
comparable R&D investment figures across the spectrum of neglected diseases, including 
HIV/AIDS and TB funding, as a starting point for informed decision making of funders and 
politicians. 
As a second large initiative, and also funded by the BMGF, the Treatment Action Group 
(TAG) has been providing an annual overview of the global TB funding expenditures since 
2005. TAG is a New York based independent AIDS advocacy group fighting for better 
treatment, a vaccine, and a cure for AIDS. In the context of their TB/HIV project, TAG has 
been compiling the ‘Treatment Action Group’s report on funding trends for tuberculosis (TB) 
research and development (R&D)’, monitoring global spending for TB R&D from the baseline 
year 2005 through currently 2010 (JIMÉNEZ-LEVI, 2012). 
In that sense, streamlining and coordination of efforts have become central elements of 
funding strategies in Europe. To overcome fragmentation and optimize the efficiency of use 
of resources, the EC has created large Framework Programmes (FP), bundling all research 
activities to large multi-annual programmes. They are characterized by a strong emphasis on 
collaborative research between scientists in different countries and different sectors. Since 
their introduction in 1984, they have become the main tool to fund cooperative research in 
Europe (LANG et al., 2010). Within the current FP7, the cooperation scheme is unique in its 
internationality, and has been taken up very positively by the scientific community (HANSEN 
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et al., 2012). HIV/AIDS, malaria, and tuberculosis became a specific research focus already in 
FP6, which ran from 2002 – 2006 and allocated €450 million in PRD R&D. To continue these 
efforts within FP7, the EC organized a conference on PRD in Brussels on Nov 13-14 2008, 
entitled Challenges for the Future: research on HIV/AIDS, malaria and tuberculosis, with the 
aim to develop views on how to focus PRD research under the new FP7 (GRYSEELS et al., 
2009).  
In that context and in the same month, the EC has initiated funding for the ‘European 
Network for global cooperation in the field of AIDS and TB’ (EUCO-Net; www.euco-net.eu), a 
project that brought together experts from Europe and several regions with a particularly 
high burden of HIV/MTB co-infection, to develop an evidence-based joint research agenda 
for AIDS and TB research (SESTER et al., 2010). It is in the framework of this project that the 
majority of the work presented in this thesis has been performed. 
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1.10 Specific aims 
TB surveillance data collected by WHO and ECDC are published annually, but data are shown 
only for the WHO European Region in summary, and selected individual countries. 
Particularly, no overview of the situation of HIV/MTB co-infection has been available. TB 
diagnostic practice is inconsistent, with a variety of diagnostic tests in use, but non-existing 
or differing national guidelines throughout Europe. To facilitate evidence-based, informed 
decision making both with regards to development of EU-specific guidelines and the 
elaboration of a joint research agenda, this thesis aimed to 
 provide an overview of the epidemiology of TB (including MDR/XDR-TB) and HIV/TB 
co-infection in all 27 EU member states, 
 compare TB diagnostic standards and the availability of tests in Europe and high 
burden areas, 
 assess the suitability of IGRAs for the diagnosis of active TB as a basis for new EU-
specific diagnostic guidelines, 
 prepare and coordinate the development of recommendations for future HIV/TB 
research activities (in Europe and globally) and synthesize them in a Roadmap, 
 align these suggestions with ongoing initiatives and trends regarding HIV/AIDS and TB 
funding within the EU research funding portfolio, and to 
 summarize the most relevant facts about HIV/MTB co-infection in the form of a short 
film geared towards the media and key decision makers. 
The main aims, outputs and addressees of this thesis are summarized in Figure 5. 
 
 
 
 
 
 
Figure 5. Activities described 
in this thesis, 
including their 
interrelation, 
results and impact. 
Solid frame: activity 
mainly performed 
by or led by C Giehl. 
Dotted frame: main 
responsibility 
shared between C. 
Giehl, A. 
Meyerhans, and M. 
Sester. 
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2 Materials and methods 
2.1 Abbreviations 
AFB acid-fast bacilli 
AIDS acquired immunodeficiency syndrome 
BAL bronchoalveolar lavage 
BCG Bacille Calmette-Guérin 
BMGF Bill and Melinda Gates Foundation 
CFP-10 culture filtrate antigen 10 
CSF cerebrospinal fluid 
DST drug susceptibility testing 
EC European Commission 
ECDC European Centre for Disease Prevention and Control 
EEA European Economic Area 
ELISA enzyme-linked immunosorbent assay 
ELISPOT enzyme-linked immunospot (assay) 
ESAT-6 early secretory antigenic target 6 
EU European Union 
EU27 the 27 member states of the European Union 
FP7 the Seventh Framework Programme of the European Union 
G-FINDER Global Funding of Innovation for Neglected Diseases 
HIV human immunodeficiency virus 
ICD-10 International Classification of Diseases, 10th edition 
IFNγ Interferon gamma 
IGRA Interferon gamma release assay 
LTBI latent tuberculosis infection 
M. Mycobacterium 
MDG Millennium Development Goal 
MDR-TB multidrug-resistant tuberculosis 
MTB Mycobacterium tuberculosis 
NGO non-governmental organization 
PBMC peripheral blood mononuclear cell 
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PHA phyto-hæmagglutinin 
PPD purified protein derivate 
PPP public private partnership 
PRD poverty-related diseases 
QFT-GIT QuantiFERON Tb-Gold In-Tube 
R&D research and technological development 
TAG Treatment Action Group 
TB tuberculosis 
TBNET Tuberculosis Network European Trials Group 
UNAIDS Joint United Nations Programme on HIV/AIDS 
WHO World Health Organization 
XDR-TB extensively drug-resistant TB 
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2.2 Epidemiological data 
2.2.1 Data collection 
A collection of TB epidemiological data and related information on HIV/MTB co-infection was 
compiled for 2008 as a reference year - the latest year for which the full range of data was 
already available at the time of collection - for all 27 EU member states, including both 
surveillance data (i.e. reported cases) and WHO estimates. 
Reported case numbers for TB, MDR-TB, XDR-TB, and TB-related deaths in the European 
Union were extracted from the ‘ECDC surveillance report: tuberculosis surveillance in Europe 
2008’ (EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL, 2010b), and 
complemented with case numbers provided by countries to WHO as available in the global 
WHO database (freely accessible at http://www.who.int/tb/country/data/download/ 
en/index.html). Where data for 2008 were not available, the value of the closest possible 
year was collected, preferably for the next following year, and the deviation from the 
standard reference year is clearly indicated in the respective tables. 
Estimated case numbers generated by WHO for the same reference year were extracted 
from the WHO report 2011 on global tuberculosis control (WORLD HEALTH ORGANIZATION, 
2011b) and the global WHO database. Following WHO recommendations (WORLD HEALTH 
ORGANIZATION, 2012a), estimated case numbers for the reference year 2008 presented or 
used herein are taken from the latest WHO report only (which in many cases provides 
updates on estimates reported in previous reports), i.e. updated as compared to data 
previously published in the context of this thesis (GIEHL et al., 2011). The accuracy of 
estimates is said to have significantly improved due to a clear increase in availability of data, 
and improved calculation methods. Furthermore, for better readability, only best estimates 
are indicated here (without lower and upper bounds as calculated by WHO, defined as the 
2.5th and 97.5th percentiles of outcome distributions produced in simulations). 2008 
population data for the calculation of prevalence and incidence rates (see below) were 
obtained from the WHO global database, with totals available for all 27 EU countries. 
2.2.2 Calculation of prevalence, incidence, and mortality 
Prevalence (TB; MDR-TB; XDR-TB) was calculated as the total number of cases (all forms of 
TB; MDR-TB; XDR-TB) per 100,000 population. Incidence (TB; MDR-TB) was calculated as the 
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number of new and relapse cases (of all forms of TB; MDR-TB) per 100,000 population. 
Mortality was calculated as the total number of reported deaths caused by the disease in 
HIV-negative people per 100,000 population. TB deaths among HIV-positive people are to be 
classified as HIV deaths according to the latest revision of the international classification of 
diseases (ICD-10) and are thus not included in TB mortality calculations. 
Prevalence and incidence were calculated both from reported cases and from estimates 
(resulting in ‘estimated prevalence’ and ‘estimated incidence’), with the basis for 
calculations clearly indicated in presented tables or graphs. 
2.3 Diagnostic standards and disease management  
2.3.1 Data collection on diagnostic standards 
To assess country standards with regards to use of diagnostic tests and resistance testing in 
Europe, and to compare those with the situation in several high burden regions, an 
electronic survey was performed among health care practitioners in Europe, India, Russia, 
South America, and Sub-Saharan Africa. 
Data collection 
Respondents were asked to indicate which test is used for standard diagnostic purposes in 
their state sector, both for contact tracing and for diagnosis of active TB in adults, and how 
commonly the respective test is used (Figure 6): 
1 – very common 
2 – common 
3 – rare 
4 – not at all / not available 
In addition, a free text field allowed the reporting person to further specify the transmitted 
information, or report on difficulties in information retrieval, or inconsistencies of available 
data. 
 
Figure 6. Table to be filled in by health care practitioners in the electronic survey. 
TST X-ray IGRA TST X-ray IGRA microscopy culture PCR phenotypic genotypic
contact tracing TB diagnostics resistance testing
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The questionnaire was sent to healthcare practitioners in those European countries with the 
highest TB prevalence, highest number of reported TB cases, or highest MDR-TB prevalence 
(top five each) as well as in India, Russia, South America, and selected Sub-Saharan African 
countries. 
2.3.2 Meta-analysis of data on diagnostic tests (TST and IGRAs) 
To assess the capacity of commercially available IGRAs to diagnose active TB in humans in 
blood and in extrasanguinous fluids, a systematic review was conducted together with a 
working group of the Tuberculosis Network European Trialsgroup (TBNET), a non-profit, non-
governmental peer-initiated scientific organization to collaboratively address research 
priorities in the area of tuberculosis in Europe (SESTER et al., 2011; GIEHL et al., 2012). The 
review was commissioned by the ECDC and performed according to the ‘Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses’ (PRISMA) statement (MOHER et al., 2009) 
and the ‘Quality Assessment of Diagnostic Accuracy Studies’ (QUADAS) checklist (WHITING 
et al., 2003). 
Study selection 
To identify studies for potential inclusion, PubMed, EMBASE and the Cochrane-controlled 
central register of controlled trials were searched using the keywords ‘tuberculosis’, ‘T-spot’, 
‘Quantiferon’, ‘interferon-gamma release assay’, ‘IGRA’, ‘ESAT-6’ and ‘CFP-10’. Existing 
systematic reviews and meta-analyses were screened manually for additional references. 
The results from this search were compiled into an initial database from which duplicate 
citations were eliminated (both ‘real’ duplicate listings of the same study and any study 
using the same patients as an already included study). Title and abstract of each citation 
were screened independently by two experts to select relevant studies. Where different 
judgments on the inclusion of a study were made, abstract and title were revisited jointly by 
the two experts to reach a consensus decision. 
To be included, studies had to report on the assessment of commercially available IGRAs in 
individuals with a clinical suspicion of active tuberculosis, performed on blood or biological 
fluids other than blood (ascites, BAL-fluid, CSF, pericardial fluid, pleural effusion). 
Publications appearing in a language other than English or before January 2001 or after 
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November 2009 were excluded. In a final selection step, the full text articles of the 
remaining publications were screened to confirm their inclusion in the meta-analysis. 
Studies were excluded if belonging to one of the following groups:  
(1) case reports, editorials, or review articles 
(2) laboratory studies 
(3) animal studies 
(4) studies using other assays than QFT-GIT or T-SPOT.TB 
(5) studies which were not performed according to manufacturers’ instructions 
(6) studies where tuberculosis was not confirmed by MTB culture, histopathological 
findings and/or nucleic acid amplification tests (NAAT) in more than 50% of cases 
(7)  studies performed with cut-offs for positive test results that are not used in Europe 
(8)  studies where IGRA testing was performed after more than two weeks of tuberculosis 
treatment.  
Criteria 5 and 7 were only applied to studies on IGRAs performed on blood. 
Data extraction 
From those studies that were finally included, data were extracted and merged into a joint 
excel spreadsheet. Key data collected comprised the study period, study design, country in 
which the study was conducted, gender distribution, age groups (adults vs. children), 
proportion of immunocompromised patients, BCG vaccination status, type of test 
performed, sensitivity and specificity for all tests compared, specimen on which the test was 
performed (for IGRAs), proportion of indeterminate results, proportion of AFB sputum 
positive patients, and proportion of culture confirmed cases. Where data could not be 
extracted directly from the publication, authors were contacted by email or telephone to 
retrieve the missing information. 
Statistical analysis 
Combined estimates of sensitivity, specificity and diagnostic odds ratio were computed. 
Indeterminate results were excluded before calculation of sensitivity and specificity. Forest 
plots were constructed to graphically assess both the variability of the estimates of the 
diagnostic parameters, and the weight of every sample size in the calculation of the pooled 
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estimates (weighted means). A random-effects meta-analysis was performed in order to 
account for the expected between-study variability for each study, along with a pooled 
estimate using the software for statistical analysis Stata 9.0 (StataCorp, College Station, TX, 
USA) and MetaDisc software, version 1.4 (ZAMORA et al., 2006). Inconsistency (statistical 
heterogeneity) among studies was assessed by the conventional chi-squared test for 
heterogeneity and by calculating the I2 statistic in order to highlight the effect of true 
variability rather than sampling error on the overall variation in diagnostic estimates. 
Statistical analysis was performed by TBNET member Giovanni Sotgiu from the Institute of 
Hygiene and Preventive Medicine, University of Sassari, Sassari, Italy. 
2.4 Definition of research priorities within the EUCO-Net project 
Following a baseline assessment of epidemiological data on HIV/AIDS and TB, and of 
diagnostic standards both in Europe and four additional focus areas (Russia, India, South 
America and Sub-Saharan Africa), a collaborative process to identify joint research priorities 
was initiated within the FP7 project EUCO-Net, with the aim to elaborate a Roadmap on 
HIV/MTB co-infection, identifying global research needs and focus topics for future 
collaborative research (SESTER et al., 2010). 
For that purpose, a panel of 60 experts was convened on July 23-24 2009 in Stellenbosch, 
South Africa, bringing together stakeholders from Europe and the four additional focus areas 
with complementary backgrounds, including scientists from academia, research institutes 
and the industrial sector, health care professionals, policymakers, activists, and people living 
with HIV/MTB. 
2.4.1 Selection of experts for preparation of the EUCO-Net Roadmap 
To ensure an appropriately balanced composition of the expert group, a systematic 
approach of expert selection was chosen, aiming at a total participant number of 60, with 20 
experts from Europe, and 10 experts from Russia, India, South America, and Sub-Saharan 
Africa, respectively. Each region was to include the same number of HIV and TB experts. 
‘Core group experts’, i.e. partners of the EUCO-Net project consortium, were to select their 
group peers; each expert was requested to suggest up to 6 ‘additional experts’, if possible 
from different sectors and with complementary backgrounds to achieve a mix of participants 
from industry, academia, patient associations, advocacy groups, including clinicians, 
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scientists, and policy makers. Where the number of suggested experts exceeded the 
available slots per region, the final selection was done by the coordinating team (M. Sester, 
A. Meyerhans, and C. Giehl), based on a pre-defined set of quality criteria. 
The targeted number of participants was 60, of which 30 with a background in HIV/AIDS 
research, and 30 from the TB field. Europe was to be represented by 10 HIV/AIDS and 10 TB 
experts, while all other regions were invited to suggest 5 experts each (Figure 7). 
 
Figure 7. Approach for selection of workshop participants. 
2.4.2 Assessment of baseline situation and definition of focus topics 
To ensure that all experts were adequately informed of the existing knowledge base, and 
starting from the same point of knowledge, regional reports were presented by each of the 
five target regions, including important focus topics selected by the presenter. 
Following this, experts were subdivided into ad-hoc committees by research subject area. 
The following three work groups were established: i) ‘Therapy and drug interactions’; ii) 
‘Diagnostics’; and iii) ‘Translation of research’. 
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Experts were allocated to the work groups prior to the beginning of the workshop, based on 
their publication history and current focus of activity. Where allocation to two or more 
groups was possible, additional factors such as the best possible balance between the 
different working groups or expressed personal preferences were taken into account. 
Presented focus topics were discussed and complemented in each group, and each working 
group presented a maximum of five jointly elaborated topics at the end of the group session.  
Following the workshop, the core group experts came together to a Roadmap Roundtable in 
order to refine the identified common research needs and to define final structure and 
content of the Roadmap document. A detailed work plan for the finalization of the Roadmap 
was agreed, including task allocation and exact time planning. 
2.4.3 Online follow-up, consensus procedure, and writing of the Roadmap 
Workshop participants received access to a password protected online platform which 
allowed them to further comment on the draft document that was produced as an outcome 
of the workshop and roundtable discussion. Topic suggestions as elaborated during the 
workshop were put up for further discussion and comments online from August 1 - 
September 30, 2009. Participants had the opportunity to edit the draft document by adding 
comments in 'track changes' mode, and upload edited draft versions under 'commented 
versions', or to initiate or participate in a discussion on a message board. 
After closing of the online follow-up phase, the proposed ‘priority areas for joint AIDS/TB 
research and concerted actions’ were divided into four main sections (basic sciences, clinical 
research, diagnostics, training and networking). A writing committee consisting of work 
group and discussion leaders at the workshop, one NGO representative per disease, and the 
coordinating committee was nominated to lead the consensus and writing process of the 
document (P. Cuchi, C. Giehl, B. Kampmann, R. McNerney, A. Meyerhans, A. Kritski, C. Lange, 
G.B. Migliori, M. Sester, G. Walzl, C. Wingfield, in alphabetical order). Introductory 
paragraphs for the four sections were written by the writing group members. Final editing of 
the Roadmap was performed by M. Sester, A. Meyerhans, and C. Giehl. 
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2.5 Funding analysis 
2.5.1 Global funding 
Data extraction 
One of the elements to be taken into account when elaborating priority topics for future 
research funding was the current allocation of total global funding to the fields of HIV/AIDS 
and TB research. For that purpose, data on funding allocation for HIV/AIDS and TB research 
were extracted from TAG reports (JIMÉNEZ-LEVI, 2012) and G-FINDER database (MORAN et 
al., 2009a) and merged into a joint excel spreadsheet. Key data collected comprised the total 
funding for HIV/AIDS, total funding for TB, and allocation of funding according to different 
fields of research (HIV/AIDS: basic research, diagnostics, microbicides, and vaccines; TB: 
basic research, diagnostics, drugs, vaccines, unspecified). Secondly, as the Roadmap was 
primarily directed to the EC, data on the allocation of EC-funding from FP6 & FP7 to different 
fields of research were extracted from the TAG report (data available for 2005 – 2010). 
Calculations 
Based on G-FINDER data, the relation of HIV/AIDS vs. TB funding was calculated. Secondly, 
G-FINDER & TAG TB funding data were compared with each other to check consistency or 
spot differences. Lastly, based on TAG data, the development of FP6/FP7 TB funding 
disbursement according to different fields of research since 2005 was calculated. 
2.5.2 HIV/AIDS and TB in FP7 
Project selection 
To identify projects to be included in the overview, the project database of the infectious 
diseases unit of the EC’s DG Research Directorate F Health 
(http://ec.europa.eu/research/health/infectious-diseases/index_en.html) was consulted in 
May 2012. The site lists all FP7 HEALTH projects dealing with HIV/AIDS, Malaria and 
Tuberculosis. Possible search functions include grouping according to disease. Thus, in a first 
steps, all projects listed as ‘HIV/AIDS’ projects and ‘TB’ projects were selected. In a second 
step, the full project database was searched using the keywords ‘tuberculosis’, ‘TB’, ‘HIV’, 
‘AIDS’. 
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Projects were selected based on the acronym and full project title resulting from the two 
searches. To confirm the inclusion, project abstract and information presented on the 
project websites were reviewed. 
Data extraction 
Data on ongoing and completed projects were extracted from detailed project factsheets as 
provided by the project database of the infectious diseases unit, or from project websites. 
Data collected include title and abstract of the project, funding scheme, total project funding 
(‘maximum requested EC contribution’), project start date, study duration, country of 
coordinating institution, and countries of project partner institutions. All data were 
transferred into one excel spreadsheet to allow for both, joint and separate analysis and 
calculations. 
Calculations 
Allocation to HIV/AIDS or TB or co-infection was based on the information contained in the 
project factsheet and the public project website. Where title and/or summary indicated a 
clear main focus on TB, the project was categorized as ‘TB (only)’; where title and summary 
of the project indicated a clear main focus on HIV/AIDS, the project was categorized as 
‘HIV/AIDS (only)’. For the calculation of ‘HIV/AIDS-only funding’ or ‘TB-only funding’, the EC 
contribution dedicated to co-infection projects was allocated 50/50 to each. 
Total allocated funding was divided by the total running time per project, resulting in a 
project-specific average monthly funding that was distributed equally over the project 
lifetime. For the calculation of cumulative funding over time, the total funding sum for all 
ongoing projects was calculated for each month. 
2.6 Short film production 
As the second main EUCO-Net outcome to raise awareness for the issue of HIV-TB co-
infection, in addition to the Roadmap, a short film was produced in collaboration with a 
professional film production company, and distributed to decision makers and the public at 
large. Before the actual filming, key issues such as the target audience, core information to 
be conveyed, and the means to convey the information were defined as follows: 
Target audience: Funding agencies, policy makers, and the general public 
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Key information to be conveyed: 
HIV/MTB co-infection is a problem 
 in Europe and many high burden regions 
 due to mutual and manifold interactions, the two diseases represent a particular 
challenge when affecting the same patient 
 TB and HIV/AIDS are usually tackled individually (both in research as well as in the 
clinics), but joint efforts are needed 
 Therefore: EUCO-Net has been initiated, as a global, interdisciplinary initiative 
 EUCO-Net is coordinated by a team of 1 HIV and 1 TB expert at Saarland University 
 Aims of the project: assessment of status quo, needs, and development of a 
“Roadmap” with recommendations for further research 
Means to convey the information: 
 A comic strip illustrating the immunological basics of HIV/MTB co-infection (reduce 
to the minimum and illustrate graphically) 
 Kickoff meeting scenes and interviews with scientists (providing additional 
information, examples from different regions, explaining research needs) 
 South Africa as an example setting, showing people affected by the two diseases. 
For the comic strip, the immunological basics of HIV/MTB co-infection were outlined and 
prepared as drawings to develop the storyline. Examples are shown in Figure 8. 
            
Figure 8. Drawings for the development of the comic strip storyline. 
To guide the translation of the agreed elements into the final comic sequence, an animated 
presentation was prepared, linking the text to be included directly with the visual elements. 
Meeting scenes and interviews with partners from the different target regions, all 
emphasizing the severity of the problem, were included to illustrate the international aspect 
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and global relevance of the co-infection issue. Two visits to homes of patients co-infected 
with HIV and MTB and a doctor’s visit of a mother with her young son were included to show 
‘real’ people affected by the diseases, adding an emotionalizing impression to the scientific 
contents of the film. Filming was prepared and coordinated by staff members of 
Stellenbosch University, including the collection of informed consent by the individuals to be 
featured in the film. To respect the stigma attached to TB and HIV, faces of the patients 
shown in the film were anonymized for those sequences that were not only meant for 
restricted scientific audiences. Locations and timeline of the filming are shown in Table 3. 
Table 3. EUCO-Net filming: Locations, dates and scenes captured. 
 N° location date  Scenes 
fi
lm
in
g 
 
1 Brussels, 
Belgium 
Nov 13-14, 
2008 
Interview scenes with selected experts representing each 
of the EUCO-Net target regions 
Brussels as headquarters of the European Commission 
and venue of the EUCO-Net kickoff-meeting 
2 Saarland, 
Germany  
Dec 12, 
2008 
Location of the coordination team at Saarland University 
& Eurice GmbH; laboratory visit to the Fraunhofer 
Institute for Biomedical Research  
3 Cape Town, 
South Africa 
Jan 19-23, 
2009 
Example of a high burden setting where patients, 
clinicians and basic researchers are very closely 
interlinked: 
Impressions from a community clinic and home visits to 
patients suffering from co-infection; portrait of a research 
nurse taking care of these patients, and taking samples to 
a laboratory at Stellenbosch University; interview with 
scientists at Stellenbosch University 
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3 Results 
3.1 Epidemiology of TB and HIV/MTB co-infection in Europe 
3.1.1 TB Epidemiology 
22 out of the 27 countries (81.5%) in the European Union provided a full set of data of TB 
epidemiology (total TB cases at the time of data entry, new TB cases during year of 
reference, and TB-related deaths during the year of reference), while for Austria, Belgium, 
Luxembourg, Portugal and Slovakia, at least one of these values were unavailable (Table 4). 
Table 4. EU27: Reported TB cases and deaths, calculated prevalence, incidence and mortality. 
country TB cases 
calculated 
TB 
prevalence 
per 
100,000 
new TB 
cases 
calculated 
TB 
incidence 
per 
100,000 
TB deaths 
(2007, 
unless 
indicated 
otherwise) 
calculated 
TB 
mortality 
per 
100,000 
total 
population 
Austria - - - - 49* 5.87 834,806 
Belgium 1,006 9.5 779 7.3 - - 10,602,167 
Bulgaria 3,151 41.5 2,838 37.4 275 3.62 7,591,322 
Cyprus 50 4.6 17 1.6 1 0.09 1,077,001 
Czech 
Republic 
868 8.4 807 7.8 70 0.67 10,377,359 
Denmark 367 6.7 330 6.0 14 0.25 5,497,312 
Estonia 444 33.1 354 26.4 43 3.20 1,342,145 
Finland 350 6.6 331 6.2 56 1.05 5,316,334 
France 5,812 9.4 3,355 5.4 667 1.07 62,098,413 
Germany 4,543 5.5 3,623 4.4 139 0.17 82,475,271 
Greece 669 5.9 538 4.8 96 0.85 11,291,807 
Hungary 1,606 16.0 1,321 13.2 231* 2.30 10,021,886 
Ireland 470 10.8 335 7.7 45 1.03 4,352,866 
Italy 4,418 7.4 3,409 5.7 407** 0.68 59,891,479 
Latvia 1,070 47.1 918 40.4 144 6.34 2,271,198 
Lithuania 2,250 67.0 1,892 56.3 284* 8.45 3,359,799 
Luxembourg 28 5.8 - - - - 486,781 
Malta 53 12.8 46 11.1 6 1.45 413,946 
Netherlands 997 6.0 948 5.7 54 0.33 16,503,263 
Poland 8,081 21.1 7,061 18.5 775 2.03 38,218,462 
Portugal 2,995 28.2 2,703 25.4 - - 10,634,612 
Romania 24,786 114.8 18,774 87.0 1,639* 7.59 21,589,544 
Slovakia 633 11.6 510 9.4 - - 5,441,304 
Slovenia 213 10.6 198 9.8 29 1.44 2,018,172 
Spain 8,214 18.2 6,769 15.0 475 1.05 45,146,258 
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country TB cases 
calculated 
TB 
prevalence 
per 
100,000 
new TB 
cases 
calculated 
TB 
incidence 
per 
100,000 
TB deaths 
(2007, 
unless 
indicated 
otherwise) 
calculated 
TB 
mortality 
per 
100,000 
total 
population 
Sweden 552 6.0 456 4.9 64** 0.69 9,236,872 
UK 8,655 14.1 6,520 10.6 435* 0.71 61,270,318 
total EU27 82,281 16.8 64,832 13.2 5,998 1.23 489,360,697 
TB deaths among HIV-positive people are to be classified as HIV deaths according to the latest revision of the 
international classification of diseases (ICD-10) and are thus not included in TB mortality calculations. 
Numbers referred to in the text are marked in red. 
*: reference year 2008 
**: reference year 2006 
The top five countries within the EU27 with the highest number of TB cases, as well as with 
the highest calculated prevalence, incidence and mortality are summarized in Table 5. 30% 
of all reported TB cases in the EU27 are located in Romania, followed by UK and Spain with 
more than 10% each. Taking into account the different population numbers, the top five 
countries in order of decreasing TB prevalence according to reported cases (all types of TB) 
are Romania (114.8), Lithuania (67.0), Latvia (47.1), Bulgaria (41.5), and Estonia (33.1 per 
100,000 population). The same five countries also show the highest TB incidence rates, 
decreasing in the same order as for prevalence. 
When it comes to TB mortality, Romania is surpassed in mortality by Lithuania. Notably, 
Austria enters the stage as the country with the fourth highest TB mortality in Europe. Even 
though TB is a notifiable disease in Austria and needs to be reported by physicians to the 
district public health authorities, the country has not passed on the information on TB cases 
to WHO, and the latest available case numbers date back to 2006, thus were not included in 
this compilation. 
Table 5.  EU27: Top 5 countries for reported TB cases, calculated prevalence, incidence and mortality. 
  TB cases 
calculated 
TB 
prevalence 
per 100,000 
population 
calculated 
TB incidence 
per 100,000 
population 
calculated 
TB mortality 
per 100,000 
population 
rank 1 Romania Romania Romania Lithuania 
rank 2 UK Lithuania Lithuania Romania 
rank 3 Spain Latvia Latvia Latvia 
rank 4 Poland Estonia Estonia Austria 
rank 5 France Bulgaria Bulgaria Bulgaria 
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With regards to geographical distribution, the burden of TB infection and disease is 
distributed unevenly within the EU27, with the highest rates of prevalence and incidence in 
Eastern European countries, Portugal and Spain (Figure 9 and Figure 10). 
 
Figure 9. EU27: TB prevalence per 100,000 population in 2008. 
 
 
 
 
 
 
 
 
 
Figure 10. EU27: TB incidence per 100,000 population in 2008. 
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Drug-resistant tuberculosis in Europe 
Data on drug-resistant TB in the EU are less complete; only 11 out of the 27 member states 
(40.7%) provided information on the full set of information (number of total MDR-TB cases, 
number of new MDR-TB cases, and total number of XDR-TB cases) in 2008. Italy reported no 
data on resistant TB at all, though cases are described in the literature (e.g.MIGLIORI et al., 
2007). Information on new MDR-TB cases is further missing from Luxembourg, and data on 
XDR-TB were reported only by Belgium, Bulgaria, Cyprus, Czech Republic, Estonia, Latvia, 
Romania, Slovakia, Spain, Sweden, and the UK. 
Table 6. EU27: Reported MDR & XDR-TB cases, calculated prevalence and incidence in 2008 (unless 
indicated otherwise). 
country 
MDR 
cases 
calculated 
MDR 
prevalence 
per 
100,000 
population 
new MDR 
cases 
calculated 
MDR 
incidence 
per 
100,000 
population 
XDR cases 
calculated 
XDR 
prevalence 
per 
100,000 
population 
total 
population 
 
Austria 22* 2.64 5* 0.60 - - 834,806 
Belgium 22 0.21 15 0.14 2 0.02 10,602,167 
Bulgaria 32 0.42 0 0.00 0 0.00 7,591,322 
Cyprus 1 0.09 0 0.00 0 0.00 1,077,001 
Czech Republic 11 0.11 10 0.10 1 0.01 10,377,359 
Denmark 2 0.04 0 0.00 - - 5,497,312 
Estonia 74 5.51 42 3.13 9 0.67 1,342,145 
Finland 1 0.02 1 0.02 - - 5,316,334 
France 27 0.04 16 0.03 - - 62,098,413 
Germany 45 0.05 16 0.02 - - 82,475,271 
Greece 14* 0.12 9* 0.08 - - 11,291,807 
Hungary 16 0.16 8 0.08 - - 10,021,886 
Ireland 3 0.07 2 0.05 - - 4,352,866 
Italy - - - - - - 59,891,479 
Latvia 129 5.68 83 3.65 19 0.84 2,271,198 
Lithuania 276 8.21 113 3.36 - - 3,359,799 
Luxembourg 0* 0.00 - - - - 486,781 
Malta 1 0.24 0 0.00 - - 413,946 
Netherlands 13 0.08 11 0.07 - - 16,503,263 
Poland 52 0.14 18 0.05 - - 38,218,462 
Portugal 28 0.26 19 0.18 - - 10,634,612 
Romania 816 3.78 130 0.60 54 0.25 21,589,544 
Slovakia 4 0.07 1 0.02 0 0.00 5,441,304 
Slovenia 2 0.10 1 0.05 - - 2,018,172 
Spain 76 0.17 31 0.07 3 0.01 45,146,258 
44 
country 
MDR 
cases 
calculated 
MDR 
prevalence 
per 
100,000 
population 
new MDR 
cases 
calculated 
MDR 
incidence 
per 
100,000 
population 
XDR cases 
calculated 
XDR 
prevalence 
per 
100,000 
population 
total 
population 
 
Sweden 12 0.13 7 0.08 1 0.01 9,236,872 
UK 53 0.09 38 0.06 1 0.00 61,270,318 
total EU27 1,732 0.35 576 0.12 90 0.02 489,360,697 
*: reference year 2009 
Numbers referred to in the text are marked in red. 
 
Table 6 shows that Romania has the highest number of reported MDR-TB cases (816), 
followed by Lithuania (276), Latvia (129), Spain (76) and Estonia (74). Based on these 
reported case numbers, the highest MDR-TB incidence, however, has been reported for 
Lithuania (8.21 per 100,000 population), Latvia (5.68) and Estonia (5.51). With a prevalence 
of 2.64 per 100,000 population, Austria again ranks among the top five countries in the EU. 
The geographic distribution of MDR-TB across Europe is shown in Figure 11. 
 
Figure 11. EU27: MDR-TB prevalence per 100,000 population in 2008. 
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3.1.2 Epidemiology of HIV/MTB co-infection 
3.1.2.1 TB/HIV surveillance data 
Surveillance data on HIV infected individuals with active TB (‘TB/HIV’) are very limited. Only 
14 out of the 27 EU member states (51.9%) have reported case numbers at all, and these 
countries are scattered across Europe, with no identifiable distribution pattern (Figure 12).  
 
Figure 12. Availability of co-infection data 
Of those countries for which information was available, Spain, Portugal and Romania had the 
highest absolute numbers of TB/HIV co-infected patients, with more than one third of all 
cases of co-infection reported in Europe declared in Spain (507 of 1,402; 36.2%; Table 7). 
The percentage of TB patients for whom the HIV status was known for the reference year 
2008 ranged from 0.4% (Poland) to 100% (Slovakia), with a total of 20.1% of all TB patients in 
the whole EU27. 
Table 7. Reported TB/HIV co-infection cases, calculated prevalence, and coverage of knowledge of HIV 
status among TB patients in 2008. 
country 
total 
reported 
TB/HIV 
patients 
TB/HIV 
prevalence 
per 
100,000 
total TB 
patients 
with 
known HIV 
status 
total TB 
patients 
% of TB 
patients 
with 
known HIV 
status 
Austria - - - - - 
Belgium 56 0.53 913 1,006 90.8 
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country 
total 
reported 
TB/HIV 
patients 
TB/HIV 
prevalence 
per 
100,000 
total TB 
patients 
with 
known HIV 
status 
total TB 
patients 
% of TB 
patients 
with 
known HIV 
status 
Bulgaria 0 0.00 520 3,151 16.5 
Cyprus 2 0.19 36 50 72.0 
Czech Republic 7 0.07 174 868 20.0 
Denmark 13 0.24 158 367 43.1 
Estonia 44 3.28 400 444 90.1 
Finland 4 0.08 - 350 - 
France - - - 5,812 - 
Germany - - - 4,543 - 
Greece - - - 669 - 
Hungary - - - 1,606 - 
Ireland 15 0.34 54 470 11.5 
Italy - - - 4,418 - 
Latvia 72 3.17 910 1,070 85.0 
Lithuania - - - 2,250 - 
Luxembourg - - - 28 - 
Malta 5 1.21 45 53 84.9 
Netherlands 37 0.22 261 997 26.2 
Poland - - 35 8,081 0.4 
Portugal 438 4.12 2,350 2,995 78.5 
Romania 202 0.94 6,149 24,786 24.8 
Slovakia - - 633 633 100.0 
Slovenia - - - 213 - 
Spain 507 1.12 3,937 8,214 47.9 
Sweden - - - 552 - 
UK - - - 8,655 - 
total EU27 1,402 0.29 16,575 82,281 20.1 
 Numbers referred to in the text are marked in red. 
3.1.2.2 TB/HIV estimates 
While only 1,402 cases are reported from all 27 EU member states together, the WHO is 
estimating that 3,702 patients that are suffering from active TB are also co-infected with HIV 
in the European Union (Table 8). Spain, the country with the highest reported number of TB 
cases co-infected with HIV, also ranks number one in the estimate (a total estimated number 
of 990 patients, i.e. almost double the 507 reported case number). On average, the 
estimated values deviate by nearly 40% from the reported numbers, ranging from an under-
estimation in the Czech Republic (where the best estimate of total co-infected patients is 
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lower than the reported number of cases) to an estimate that exceeds the reported number 
of cases by more than 200%, as shown for Romania (202 reported vs. 630 estimated cases). 
Table 8. TB/HIV co-infection cases, surveillance data vs. estimates, and estimated mortality. 
country 
total 
reported 
TB/HIV 
patients 
estimated 
total 
TB/HIV 
cases 
calculated 
prevalence 
based on 
estimated 
TB/HIV 
cases 
difference 
between 
reported 
cases and 
estimate 
deviation 
between 
reported 
number 
and 
estimate 
[%] 
estimated 
TB/HIV 
deaths 
calculated 
TB/HIV+ 
mortality 
based on 
estimates 
per 
100,000 
population 
Austria - 35 4,19 - - 3 0.36 
Belgium 56 63 0,59 7 12.5% 5 0.05 
Bulgaria 0 3.3 0,04 3.3 - 9 0.12 
Cyprus 2 - - - - - - 
Czech Republic 7 5.5 0,05 -1.5 -21.4% 1 0.01 
Denmark 13 18 0,33 5 38.5% 2 0.04 
Estonia 44 49 3,65 5 11.4% 18 1.34 
Finland 4 5.9 0,11 1.9 47.5% 1 0.02 
France - 380 0,61 - - 57 0.09 
Germany - 99 0,12 - - 11 0.01 
Greece - 14 0,12 - - 12 0.11 
Hungary - 15 0,15 - - 4 0.04 
Ireland 15 17 0,39 2 13.3% 2 0.05 
Italy - 210 0,35 - - 43 0.07 
Latvia 72 82 3,61 10 13.9% 12 0.53 
Lithuania - 10 0,30 - - 9 0.27 
Luxembourg - 2 0,41 - - 1 0.21 
Malta 5 5.1 1,23 0.1 2.0% 1 0.24 
Netherlands 37 45 0,27 8 21.6% 3 0.02 
Poland - 170 0,44 - - 34 0.09 
Portugal 438 560 5,27 122 27.9% 81 0.76 
Romania 202 630 2,92 428 211.9% 129 0.60 
Slovakia - 1 0,02 - - - - 
Slovenia - - - - - - - 
Spain 507 990 2,19 483 95.3% 122 0.27 
Sweden - 13 0,14 -   1 0.01 
UK - 280 0,46 -   30 0.05 
total EU27 1,402 3,702.8 0,76  Av: 39.5% 591 0.12 
Numbers referred to in the text are marked in red. 
The 35 cases estimated for Austria and the resulting prevalence of 4.19 per 100,000 
population make this country number two among all European countries, after Portugal, 
which with its 438 reported and 560 estimated patients co-infected with HIV ranks number 
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one (prevalence of 5.27 per 100,000 population). They are followed by Estonia (3.65), Latvia 
(3.61), and Romania (2.92 per 100,000) (Table 9). 
Table 9. The five countries within the EU27 with the highest prevalence and mortality, based on 
estimated cases and deaths. 
  
Estimated 
TB/HIV 
cases 
Estimated 
TB/HIV 
prevalence 
per 100,000 
population 
estimated 
TB mortality 
per 100,000 
population 
rank 1 Spain Portugal Estonia 
rank 2 Romania Austria Portugal 
rank 3 Portugal Estonia Romania 
rank 4 France Latvia Latvia 
rank 5 UK Romania Austria 
 
The geographic distribution of TB/HIV co-infection estimates is shown in Figure 13. 
 
 
 
 
 
 
 
 
Figure 13. Prevalence of TB/HIV co-infection, based on estimated case numbers. 
3.2 Variability of TB diagnostic standards and availability of tests 
Countries included 
While India and Russia are single countries, and South America comprises a number of 
countries that seemed still feasible to target, the high number of European (n=27) and Sub-
Saharan African (n=48) countries required the selection of a sub-group of countries to be 
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included in data collection. For Europe, those countries were included that belonged to the 
top five countries in Europe for at least one of the following items: total number of reported 
TB cases, highest TB prevalence, or highest MDR/XDR prevalence. The selection of African 
countries to be included was based on availability of responsive contacts through existing 
collaborations and can be regarded as a random sample. 
In total, data were requested for the following 30 countries: 
- Europe (10 countries):  
Austria (top 5 MDR/XDR prevalence), Bulgaria (top 5 TB prevalence and top 5 
MDR/XDR prevalence), Estonia (top 5 TB prevalence and top 5 MDR/XDR prevalence), 
France (top 5 TB cases), Latvia (top 5 TB prevalence and top 5 MDR/XDR prevalence), 
Lithuania (top 5 TB prevalence and top 5 MDR/XDR prevalence), Poland (top 5 TB 
cases), Romania (top 5 TB cases and top 5 TB prevalence), Spain (top 5 TB cases), UK 
(top 5 TB cases). 
- India 
- Russia 
- South America (12 countries):  
Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, 
Suriname, Uruguay, and Venezuela. 
- Sub-Saharan Africa (6 countries):  
Ethiopia, Malawi, Namibia, South Africa, The Gambia, Uganda. 
Of those, 27 (90%) reported data back that could be included in the overview. No data could 
be retrieved for Guyana, Suriname, and India. In Guyana and Suriname, the survey was not 
completed. In India, the survey respondent stated that the RNTCP (Revised National TB 
Control Program) caters to ~40-50% of the country’s TB. The rest is taken care of by the 
completely unregulated private sector, with no record of their numbers. Only very recently, 
on May 7th 2012, the government of India has declared TB a notifiable disease and officially 
banned TB serology, but the gap between health policy and its implementation is large. TB is 
still not notified by the private sector and serology is still being performed. The results 
retrieved for the remaining 27 countries are summarized in Table 10. 
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Table 10. Frequency and type of test methods applied for contact tracing and TB diagnosis, and for 
resistance testing in Europe (10 countries), Africa (6 countries), Russia, and South America (10 
countries). 
Europe: 
Africa: 
Russia: 
Latin America: 
 
TST X-ray IGRA TST X-ray IGRA microscopy culture PCR phenotypic genotypic
very common 90,0% 80,0% 10,0% 60,0% 100,0% 20,0% 100,0% 100,0% 20,0% 80,0% 20,0%
common 10,0% 20,0% 50,0% 10,0% 0,0% 20,0% 0,0% 0,0% 40,0% 20,0% 20,0%
rare 0,0% 0,0% 30,0% 30,0% 0,0% 30,0% 0,0% 0,0% 40,0% 0,0% 50,0%
not at all 0,0% 0,0% 10,0% 0,0% 0,0% 30,0% 0,0% 0,0% 0,0% 0,0% 10,0%
contact tracing TB diagnostics resistance testing
Europe
TST X-ray IGRA TST X-ray IGRA microscopy culture PCR phenotypic genotypic
very common 16,7% 33,3% 0,0% 16,7% 66,7% 0,0% 100,0% 33,3% 16,7% 50,0% 16,7%
common 0,0% 0,0% 0,0% 0,0% 33,3% 0,0% 0,0% 16,7% 0,0% 0,0% 33,3%
rare 16,7% 0,0% 0,0% 66,7% 0,0% 0,0% 0,0% 33,3% 16,7% 16,7% 16,7%
not at all 66,7% 66,7% 100,0% 16,7% 0,0% 100,0% 0,0% 16,7% 66,7% 33,3% 33,3%
contact tracing TB diagnostics resistance testing
Africa
TST X-ray IGRA TST X-ray IGRA microscopy culture PCR phenotypic genotypic
very common 100,0% 100,0% 0,0% 0,0% 100,0% 0,0% 100,0% 100,0% 0,0% 100,0% 0,0%
common 0,0% 0,0% 0,0% 0,0% 0,0% 0,0% 0,0% 0,0% 100,0% 0,0% 100,0%
rare 0,0% 0,0% 0,0% 100,0% 0,0% 0,0% 0,0% 0,0% 0,0% 0,0% 0,0%
not at all 0,0% 0,0% 100,0% 0,0% 0,0% 100,0% 0,0% 0,0% 0,0% 0,0% 0,0%
Russia
contact tracing TB diagnostics resistance testing
TST X-ray IGRA TST X-ray IGRA microscopy culture PCR phenotypic genotypic
very common 80,0% 20,0% 0,0% 20,0% 90,0% 0,0% 100,0% 20,0% 0,0% 50,0% 0,0%
common 10,0% 70,0% 0,0% 60,0% 10,0% 0,0% 0,0% 50,0% 0,0% 30,0% 0,0%
rare 10,0% 0,0% 0,0% 20,0% 0,0% 0,0% 0,0% 30,0% 40,0% 20,0% 20,0%
not at all 0,0% 10,0% 100,0% 0,0% 0,0% 100,0% 0,0% 0,0% 60,0% 0,0% 80,0%
contact tracing TB diagnostics resistance testing
Latin America
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The information provided by respondents from all participating countries shows that overall, 
all diagnostic tests assessed are most frequently used in Europe, as compared to the other 
regions. While X-ray, microscopy and culture are routinely used for TB diagnostics by all 
European countries included in the survey, frequencies of use for the other tests vary. 
The use of IGRAs shows the highest variability among all diagnostic methods used in Europe 
and ranges from very common (11.1% in contact tracing; 22.2% in TB diagnosis) to not at 
all/not available (11.1% in contact tracing; 33.3% in TB diagnosis). However, Europe is the 
only region that reported the use of IGRAs at all. In all of the non-European countries, IGRAs 
are ‘not at all’ used or ‘not available’ for both TB diagnosis and contact tracing. 
Across regions, Sub-Saharan Africa is the area where contact tracing is least commonly 
performed with the test methods covered by the survey (no TST 66.7%; no X-ray 66.7%; no 
IGRA 100%). All other regions report TST and X-ray as commonly used methods for contact 
tracing (complemented by the frequent use of IGRAs for that purpose in Europe). 
TB diagnosis in all countries assessed heavily relies on X-ray (‘very common’: 100% in Europe 
and Russia, 90% in Latin America, and 66.7% in Africa) and microscopy (100% ‘very common’ 
throughout). 
Phenotypic drug resistance testing is more common than genotyping for the same purpose, 
and most common in Russia (100% ‘very common’) and Europe (7.8% ‘very common’, 22.2% 
‘common’) while least frequently performed in Africa, where only 50% of the countries 
report phenotypic resistance testing as ‘very common’, but the other 50% perform either no 
resistance texting at all (33.3%) or only ‘very rarely’ (16.7%). 
52 
3.3 Limited suitability of IGRAs for the diagnosis of active tuberculosis 
To assess the suitability of IGRAs for the diagnosis of active TB, a total of 844 studies were 
screened for analysis of patients with active TB using TST and/or IGRAs from blood and/or 
extrasanguinous fluid, of which 27 met the inclusion criteria (Figure 14, Annex I). 
Figure 14. Flow chart of IGRA study inclusion and exclusion. Flow diagram for study selection. 
Of these, IGRAs were performed on blood only in 18 studies (66.7%), while 9 (33.3%) 
included data on IGRAs performed on extrasanguinous fluids (5 BAL-fluids, 3 pleural fluids, 1 
ascites). The most common combination of diagnostic assays was T-SPOT.TB and TST (11/27, 
40.7%). 4 studies (14.8%) reported the use of QFT-GIT and TST, and the combination of all 
three assays, T-SPOT.TB and QFT-GIT and TST was used in another 4 studies (14.8%). 8 of the 
27 studies (29.6%) reported the use of other IGRA combinations (Table 11). 
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Table 11. Diagnostic assays used in the studies. 
diagnostic assays; number (%) 
 all individuals adults children 
T-SPOT.TB and TST 11/27 (40.8) 10/23 (43.5) 1/4 (25.0) 
QFT-GIT and TST 4/27 (14.8) 3/23 (13.0) 1/4 (25.0) 
T-SPOT.TB, QFT-GIT and TST 4/27 (14.8) 2/23 (8.7) 2/4 (50.0) 
Others (IGRAs only) 8/27 (29.6) 8/23 (34.8) 0/4 (0.0) 
 
Characteristics of included patient population 
The 27 studies included in the analysis were conducted in 35 different countries. South 
Africa was the most frequently represented country (6/35, 17.1%), followed by Italy and 
Germany (5/35, 14.3%, each), and Korea (4/35, 11.4%). 15 studies (56%) originated from a 
low-prevalence country, while 12 (44%) were performed in a high-prevalence country.  
In total, 3,821 subjects were included in all 27 studies, of which 2,262 were male and 1,559 
were female. The majority of the studies (23/27, 85.2%) included adult subjects only, while 
4/27 (14.8%) reported on tests performed on children. As it was clearly possible to 
differentiate between adult and paediatric studies, age-related sub-analyses were 
performed. Other characteristics such as immunosuppression, BCG vaccination, or on 
country of origin, were already aggregated so that it was not possible to differentiate how 
they affect the diagnostic accuracy of IGRAs. 
- Studies in adults 
Males were more represented than females (1,818 vs. 1,167). Almost half of the included 
subjects were BCG vaccinated (mean (SD) proportion of BCG immunized patients per study: 
42.1% (19.9%)). Patients with impaired immunity were enrolled in 15/18 (83%) studies; 
among these, HIV positive individuals were included in 13 (86.6%) studies. The majority of 
the studies enrolling adults described the performances of both TST and T-SPOT.TB (10/23, 
43.5%). Tuberculin PPD RT-23 SSI was used by 12/15 (80%). 
- Studies in children 
The male to female ratio was 444/392. Most subjects were vaccinated with BCG (mean 
proportion of BCG immunized patients per study: 74.2% (21.4%)). Only one of the four 
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studies (25%) included immunocompromised children. Fifty percent (2/4) of the studies 
evaluated the performances of T-SPOT.TB, QFT-GIT and TST at the same time. Tuberculin 
PPD RT-23 SSI was used by 3 of the 4 studies (75%). 
Characteristics of the TST described in the included studies 
The median (IQR) number of individuals who underwent TST was 98 (131). The reaction was 
read at 48-72 hours in almost half of the cases (44.4%). Pooled sensitivity of the TST was 65% 
(95% CI: 61%-68%; I2=89%), while pooled specificity was 75% (95% CI: 72%-78%; I2=89%). 
Pooled diagnostic odds ratio was 5.72 (95% CI: 3.78–8.65; I2=46.1%) (Table 12). 
Pooled sensitivity computed after the inclusion of the studies not showing specificity (n=4) 
was similar to the above mentioned figure (66%; 95% CI: 63%-69%; I2=93.2%), while pooled 
specificity computed after the inclusion of the studies not showing sensitivity (n=2) was 
lower (66%; 95% CI: 63%-68%; I2=94.3%). 
Characteristics of IGRAs performed on blood samples 
The median (IQR) number of individuals who underwent QFT-GIT was 94.5 (189). The total 
number of TB patients and controls with determinate results were 1,035 and 569, 
respectively. The pooled sensitivity and specificity were 80% (95% CI: 75%-84%; I2=45.3%) 
and 79% (95% CI: 75%-82%; I2=81.1%), respectively. Pooled diagnostic odds ratio was 11.5 
(95% CI: 5.1–25.7; I2=67.8%) (Table 12). The addition of the studies not showing specificity 
(n=5) did not dramatically change the pooled sensitivity (77%; 95% CI: 75%-80%; I2=64.5%). 
The median (IQR) proportion of QFT-GIT indeterminate results was 7% (12.6%). This was two 
times lower than in the samples derived from adults only (14.9% (13.6%)). The median (IQR) 
proportion of indeterminate results among children was 6.3% (3.6%). The number of 
children with determinate results was 491. Mean (SD) sensitivity in children was 79.9% 
(20.9%). Specificity was reported in only one paediatric study (85.8%). 
The median (IQR) number of individuals who underwent T-SPOT.TB was 90 (138). The total 
number of TB patients and controls with determinate results were 1,212 and 1,070, 
respectively. Pooled T-SPOT.TB sensitivity was 81% (95% CI: 78%-84%; I2=93.3%), similar to 
that of QFT-GIT sensitivity. Inclusion of papers not showing specificity (n=4) did not modify 
the above mentioned pooled T-SPOT.TB sensitivity (83%; 95% CI: 80%-85%; I2=94.2%). 
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Pooled T-SPOT.TB specificity was 59% (95% CI: 56%-62%; I2=84.5%) while the pooled 
diagnostic odds ratio was higher than that of QFT-GIT (18.86; 95% CI: 8.7–40.7; I2=81.2%).  
The median (IQR) proportion of T-SPOT.TB indeterminate results was 3.4% (5%) (5% (9.5%) 
in adults and 8% (2.5%) in children). A total of 227 children with tuberculosis and valid T-
SPOT.TB results were evaluated. Mean (SD) sensitivity was 42.2% (11%) in all cases. 
Specificity was computed in only one study (74%). 
Characteristics of IGRAs performed on extrasanguinous samples 
Nine out of the 27 articles (33.3%) described the diagnostic performance of IGRAs on 
extrasanguinous fluids: five on pleural fluid, three on bronchoalveolar lavage fluid, and one 
on ascitic fluid. None of these studies included children. 
The total number of culture confirmed cases undergoing QFT-GIT was 64 with a median 
(IQR) number of 18 (24) per single study. Pooled sensitivity and specificity for all tuberculosis 
cases (culture confirmed and non-confirmed) were 48% (95% CI: 39%-58%; I2=not assessed) 
and 82% (95% CI: 70%-91%; I2=not assessed), respectively (see Figure 15 and Table 12). 
Pooled diagnostic odds ratio was 3.84 (95% CI: 1.73–8.5; I2=not assessed). The proportion of 
QFT-GIT indeterminate results was very high, with a median (IQR) of 23.1% (40.1%). 
The total number of culture confirmed cases undergoing T-SPOT.TB was 128 with a median 
(IQR) number of 17 (26) in each study. Pooled sensitivity of the T-SPOT.TB for all tuberculosis 
cases (culture confirmed and non-confirmed) was 88% (95% CI: 82%-92%; I2=57.9%), while 
pooled specificity was 82% (95% CI: 78%-86%; I2=71.5%) (Figure 15, Table 12). Pooled 
diagnostic odds ratio, higher than that computed for QFT-GIT, was 35.83 (95% CI: 15.6–82.4; 
I2=30.8%). The median (IQR) proportion of T-SPOT.TB indeterminate results was lower (5% 
(9.8%) than that of the QFT-GIT group. 
Forest plots of sensitivity, specificity and diagnostic odds ratio are shown here only for the T-
SPOT.TB performed on extrasanguinous samples as an example (Figure 15). A detailed 
description of all results and related graphical presentations are published in full in (SESTER 
et al., 2011). Sensitivity, specificity and diagnostic odds ratio of all assays as derived from the 
meta-analysis are summarized in Table 12. 
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  Sensitivity (95%CI) Patients (n/n) 
 Lee LN et al [22]  0.95 (0.74-1.00) 18/19 
 Kim SH et al [20]  0.83 (0.36-1.00) 5/6 
 Losi M et al [23]  0.95 (0.75-1.00) 19/20 
 Jafari C et al [14]  1.00 (0.74-1.00) 12/12 
 Jafari C et al [15]  0.91 (0.81-0.97) 60/66 
 Dheda K et al [9]  0.85 (0.70-0.94) 34/40 
 Dheda K et al [8]  0.65 (0.43-0.84) 15/23 
 
 Pooled Sensitivity=0.88 (0.82-0.92) 
 Chi2=14.25; df=6 (p=0.0270) 
 Inconsistency I2=57.9% 
 
 
 
 
  Specificity (95%CI) Patients (n/n) 
 Lee LN et al [22]  0.86 (0.64-0.97) 18/21 
 Kim SH et al [20]  1.00 (0.48-1.00) 5/5 
 Losi M et al [23]  0.76 (0.53-0.92) 16/21 
 Jafari C et al [14]  1.00 (0.86-1.00) 25/25 
 Jafari C et al [15]  0.80 (0.74-0.85) 199/249 
 Dheda K et al [9]  0.60 (0.32-0.84) 9/15 
 Dheda K et al [8]  0.94 (0.79-0.99) 30/32 
 
 Pooled Specificity=0.82 (0.78-0.86) 
 Chi2=21.03; df=6 (p=0.0018) 
 Inconsistency I2=71.5% 
 
 
 
  Diagnostic OR (95%CI) 
 Lee LN et al [22]  108.00 (10.24-1,138.79) 
 Kim SH et al [20]  40.33 (1.33-1,222.98) 
 Losi M et al [23]  60.80 (6.42-575.52) 
 Jafari C et al [14]  1,275.00 (23.87-68,092.84) 
 Jafari C et al [15]  39.80 (16.27-97.37) 
 Dheda K et al [9]  8.50 (2.21-32.76) 
 Dheda K et al [8]  28.13 (5.30-149.23) 
 
 Pooled Diagnostic Odds Ratio=35.83 (15.57-82.43) 
 Cochran-Q=8.67; df=6 (p=0.1932) 
 Inconsistency I2=30.8% 
 Tau2=0.3629 
 
 
Figure 15. Forest plots of sensitivity, specificity and diagnostic odds ratio of T-SPOT.TB performed on 
extrasanguinous samples. Sensitivity data represent pooled values that were computed on all 
TB cases (culture confirmed and non-confirmed cases). All studies reported data on both 
sensitivity and specificity. Numbers in brackets indicate the number of the study as listed in 
Annex 1. 
Table 12. Sensitivity, specificity and diagnostic odds ratio of the different assays, for blood and 
extrasanguinous fluids. 
diagnostic assay / specimen sensitivity specificity 
diagnostic odds 
ratio 
TST 0.65 0.75 5.72 
QFT-GIT 
blood 0.80 0.79 11.47 
extrasanguinous 0.48 0.82 3.84 
T-SPOT.TB 
blood 0.81 0.59 18.86 
extrasanguinous 0.88 0.82 35.83 
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3.4 Research priorities are not EU-specific 
To compile a roadmap with research priorities in the area of HIV/MTB co-infection, a total of 
54 experts followerd the invitation to participate in the workshop, of which 30 (56%) 
originated from the field of HIV/AIDS and 24 (44%) had a TB background. The slight 
imbalance between HIV/AIDS and TB representatives resulted mainly from the full group of 
Russian TB experts (5 members) not showing up due to last minute organizational 
difficulties. As it was clear shortly before the workshop that only 7 of a possible 10 
participants from India would be able to attend, two additional experts from Europe and one 
expert from the USA could be invited (Figure 16). 
 
 
 
 
Figure 16. Workshop participants: Country distribution. 
Participants came from a variety of different institutional backgrounds. The majority of the 
participants worked at research institutes, followed by university representatives (18/54, 
34%), and members of non-governmental organizations (NGOs; 6/54, 11.1%) (Figure 17). 
NGOs that were represented at the workshop are ‘Kuratorium Tuberkulose in der Welt e.V.’, 
the ‘European AIDS Treatment Group’ (EATG), the US-based ‘Treatment Action Group’ (TAG), 
and the ‘Joint United Nations Programme on HIV/AIDS’ (UNAIDS; Reference Group on 
Estimates, Modelling and Projections). 8 of the 54 participants (15%) were clinicians. 
 
 
 
 
Figure 17. Workshop participants: Sector distribution. 
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The first workshop session comprised presentations of a baseline assessment for each of the 
participating regions, to provide all workshop participants with a specific insight into 
epidemiology and disease management standards in the participating regions. Each 
presentation was concluded by a summary of the key challenges for that particular region, 
followed by a personal ‘favorite’ or ‘most burning’ research question formulated by the 
presenter. While the overview of the epidemiological situation and disease management 
standards illustrated partially very distinct situations with great differences between the 
areas presented, and revealed that the EU27 - since highly heterogeneous - would require a 
more detailed and specific assessment, the suggested top priorities for further research 
were very similar between the different regions. 
Selected key presentations on the current funding situation and ongoing international 
initiatives concluded the joint baseline assessment, based on which research priorities were 
then discussed and specified in three dedicated work groups, each comprising experts from 
both high and low burden regions. Although considered of high importance, no 
recommendations were developed with regards to development of vaccines and new drugs 
since these areas have been receiving by far the most funding throughout FP6 and the first 
three years of FP7 (LANG et al., 2010) or been part of the recent FP7 calls. Therefore large 
international consortia are already in place, pursuing highly promising research avenues. 
(Topics formulated by the experts are summarized below, and published in full in ALVAREZ 
et al., 2011).  
3.4.1 Basic sciences 
Given the rise of TB due to the HIV pandemic and the limited options to manage MDR- and 
XDR-TB, workshop participants agreed that there are strong accumulated needs to improve 
(i) the mechanistic understanding of TB pathogenesis especially in the context of an HIV 
infection, (ii) the therapy options and procedures, and (iii) the diagnostic tests predictive for 
latent and active TB infection. 
Two topics in basic science were identified that deserve further attention by concerted 
research activities. The first suggested topic (see Table 13) aims to understand in greater 
detail the HIV/TB interactions within an infected host that lead to enhanced disease 
progression. The formation of MTB-induced granuloma, its role in MTB containment and 
release, and the influence of HIV and the antiviral immune response on these individual 
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functions need to be studied. A multidisciplinary approach, by clinicians, pathologists, 
immunologists, microbiologists and virologists, is needed to dissect the central cellular 
events. Increased knowledge of those mechanisms and regulatory pathways may allow the 
development of novel therapeutic strategies on how to prevent disease progression and 
contain MTB in the state of latency, or how to eliminate MTB that are kept under control by 
the immune system. The second priority topic suggests to transfer the significant progress 
which was made in understanding the development of HIV drug resistance (DEFORCHE et al., 
2008; ROSEN-ZVI et al., 2008) to the TB field, and to combine it with TB-specific problems of 
drug resistance. By understanding drug resistance pathways, defining microbial costs 
associated with resistance, considering immune and nutritional status, and incorporating the 
knowledge on drug functions and interactions, one should be able predict optimal therapy 
strategies especially when the first line drugs are failing. A consortium incorporating 
clinicians, basic researchers, drug designers and bioinformaticians should be able to 
significantly improve HIV/TB management and help to reduce the frightening burden of 
multi-drug resistance worldwide. 
Table 13. The two priority topics as recommended by the EUCO-Net experts for basic sciences. 
 N° topic title aim expected impact 
b
as
ic
 s
ci
e
n
ce
s 
1 Understanding 
MTB 
pathogenesis in 
HIV infected 
individuals by 
identification of 
microbial 
virulence and host 
factors 
Understand microbial and host 
mechanisms contributing to different 
dynamics and clinical phenotypes of HIV-
MTB co-infection. Means: highly 
standardized cohort studies, and the 
development and use of pre-clinical model 
systems (cell based or animal models).  
Prediction of MTB progression 
across different stages of the HIV 
related disease. Precise 
knowledge on the pathogen 
interaction at the molecular and 
cellular level in the context of 
this polymicrobial disease may 
contribute to the identification 
of new therapeutic targets. 
2 Personalized 
treatment 
approach for TB 
and HIV positive 
individuals based 
on drug resistance 
and therapeutic 
drug monitoring 
Optimally tailor treatment in HIV/MTB co-
infected patients through therapeutic drug 
monitoring and the development of 
algorithms that predict microbial drug 
resistance. Based on the substantial 
knowledge on genotype, phenotype and 
clinical resistance in the context of HIV, a 
similar strategy will be developed for 
infection with MTB. Main goals include the 
identification of new drug resistance 
markers, mechanisms of drug resistance, 
and evolution of microbial fitness. 
Personalized treatment 
shortening treatment duration 
and preventing therapy failure 
including resulting spread of 
drug resistant HIV/MTB variants. 
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3.4.2 Clinical sciences 
The double infection with both MTB and HIV bears many challenges with regards to patient 
management. Multiple studies have shown a substantial survival benefit from ARV therapy, 
but many patients die of TB shortly after the initiation of antiretroviral therapy (LAWN et al., 
2007), there are numerous interactions between anti-tuberculous and antiretroviral drugs 
(MA, LIENHARDT, 2009), and the pharmacokinetics of the drugs in children are incompletely 
understood (DONALD, DIACON, 2008). Advances are urgently needed as the lack of infection 
control measures in resource-poor settings, low TB treatment success rates in the large 
population of HIV-infected susceptible hosts, inadequate drug-sensitivity testing and 
overburdened MDR-TB treatment programs could combine to lead to a MDR-TB and XDR-TB 
epidemic of unmatched scale (ANDREWS et al., 2007). Key challenges in this research area 
are summarized in Table 14. 
Table 14. Four priority topics as recommended by the EUCO-Net experts for clinical sciences. 
 N° topic title aim expected impact 
cl
in
ic
al
 s
ci
e
n
ce
s 
3 TB control 
activities in HIV-
positive 
individuals: 
Cohort studies on 
HIV/AIDS 
Integrate existing and future cohort 
studies involving HIV-infected patients 
living in areas with high incidence of TB. 
Main goals should be: improving diagnosis, 
prognosis, MTB infection control, 
prevention and treatment of TB, 
understanding the pathogenesis of this co-
infection, especially immunopathogenesis, 
including IRIS and associated (predictive) 
factors increasing the understanding of 
causes of early mortality, outcomes of ART 
treatment in the context of hepatitis co-
infection, and efficacy of TB preventive 
treatment. 
A large cohort with harmonized 
and synchronized databases, 
sample collections and 
documentation from different 
health units in countries with 
high HIV/MTB co-infection will 
provide adequate statistical 
power for several retrospective 
and prospective analyses. Data 
using single cohorts or single 
countries can often not be 
evaluated and combining 
cohorts will be more cost 
effective than small and 
unpowered cohorts. 
4 Treatment and 
Prevention of TB 
in HIV-positive 
individuals: 
MultiCenter 
Clinical Trial 
Network on 
HIV/TB  
Evaluate the interaction of ART and TB 
drugs, new TB drugs, and different 
regimens for prevention of TB in HIV-
positive patients with or without ART. The 
trial will be designed to evaluate new 
treatment regimens for MDR and XDR-TB 
among HIV co-infected patients. This will 
also include the evaluation of 
pharmacokinetics and pharmaco-
surveillance of anti TB treatment in the 
context of ART. 
Increase the number of safe and 
potent drug regimens for 
prevention of TB in different 
settings of HIV infection 
according to different CD4 
counts and/or different 
epidemiological situations. 
Develop alternative safe drugs 
for the treatment of MDR and 
XDR-TB for the treatment of 
HIV-infected patients.  
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 N° topic title aim expected impact 
5 Pharmacokinetics 
of antiretroviral 
and anti-MTB 
drugs in relation 
to clinical and 
pharmacogenomic  
Optimally define the drug dosages of anti-
MTB and antiretroviral drugs in paediatric 
patients. Identify possible 
pharmacogenetic determinants of plasma 
drug levels with the final aim of 
individualizing drug dosage. Research  
Significant improvement in the 
therapeutic management of 
children infected by HIV/MTB. 
 characteristics in 
children with 
HIV/MTB co-
infection 
Should include the clinical follow-up for 
evaluation of treatment outcome in 
relation to plasma drug concentrations.  
 
 
6 Prevention of 
early mortality 
due to TB in HIV-
positive 
individuals 
initiating ART in 
geographic regions 
of high TB-
incidence 
Reduction in mortality due to TB in the first 
months following the initiation of ART in 
HIV-seropositive individuals. Possible 
geographic variations due to host and 
pathogen factors, different patterns of 
transmission as well as differences in 
treatment regimens should be elaborated. 
Main goals are the identification of risk 
factors for the TB-induced immune 
reconstitution inflammatory syndrome 
(IRIS) including markers of immune 
activation, genetic determinations and 
variables related to HIV and MTB-infection.  
An increased knowledge on the 
effect of early ART will lead to a 
reduction in early mortality due 
to TB in HIV-infected individuals 
in countries of high TB incidence 
and will increase therapeutic 
options.  
3.4.3 Diagnostics 
Because TB is a treatable disease in principle, and HIV progression can largely be slowed 
down by antiretroviral drugs, rapid and efficient diagnosis of both infections is of prime 
importance in health care. While very sensitive and specific diagnostic assays are available to 
detect HIV infection, the diagnosis of LTBI or active TB disease is more demanding, and 
particularly challenging in HIV-infected individuals. The EUCO-Net experts therefore agreed 
that more sensitive, rapid point of care tests are urgently needed to improve case finding 
and access to treatment for co-infected individuals, and have summarized the most critical 
aspects in four topic suggestions as listed in Table 15. 
Table 15. The four priority topics as recommended by the EUCO-Net experts for the area of diagnostics 
research. 
 N° topic title aim expected impact 
D
ia
gn
o
st
ic
s 
7 Diagnosis of 
latent TB in HIV-
infected patients 
Correctly identify patients latently infected 
with MTB, to predict their risk of 
progression, and to rule out active TB in 
both HIV-infected adult and paediatric 
patients. Key biomarkers should be 
identified, validated and implemented to 
be used in a clinical setting. 
This monitoring technology 
should facilitate rapid targeting 
of chemoprophylaxis and 
therapy, and will enable to 
quantify the risk for progression 
and treatment success.  
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 N° topic title aim expected impact 
8 Diagnosis of 
active TB in HIV-
infected patients 
Develop and validate improved rapid 
screening technologies for active TB in 
both HIV-infected adult and paediatric 
patients that are appropriate for use in TB-
endemic countries and poor resource 
settings. Those tests could be based on a 
variety of biological samples.  
Improved case finding, better 
treatment outcomes, reduced 
transmission, and better 
targeting of preventive therapy. 
 
9 Diagnosis of drug 
resistance in HIV-
infected patients 
Develop and validate improved screening 
technologies to assess resistance to HIV 
and TB drugs in both HIV-infected adult 
and paediatric patients. 
Prediction of treatment failure 
and quantitation of treatment 
efficacy. This will reduce 
transmission and improve 
patient care. Knowledge on drug 
resistance patterns will also 
inform infection control policies. 
10 Diagnosis of 
active TB in 
children in the 
context of HIV 
Develop and validate new approaches that 
identify active TB in the context of HIV in 
children.  
Adequate treatment of TB in 
children and to the prevention 
of HIV/MTB-related childhood 
death.  
3.4.4 Training and networking 
As guidance documents that were developed by WHO and their partners (WORLD HEALTH 
ORGANIZATION, 2004; RAVIGLIONE, UPLEKAR, 2006) as the result of joint efforts by experts 
from both fields HIV/AIDS and TB are still far from being implemented into practice on a 
large scale, the EUCO-Net experts agreed that an improvement in integrating HIV and TB 
activities, training activities and increased networking are needed on three levels: At the 
programmatic level, where national TB and HIV/AIDS programmes have problems to 
transform formal contacts into effective collaboration, at the scientific level, where HIV/AIDS 
and TB communities are largely separate, including their meetings and conferences, and at 
the clinical level, where critical gaps between the two communities hamper the successful 
management of two diseases affecting one patient at the same time. It was agreed that 
dedicated co-infection platforms would be needed on the European level, to harmonize and 
streamline efforts among the European countries. While one platform should take into 
account the specific situation in Europe as described above, a global network would be 
needed in addition, to connect the European scientific community with all major endemic 
regions as well as leading global initiatives, allowing for concerted global action. Suggested 
initiatives are summarized in Table 16. 
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Table 16. The three priority topics recommended by the EUCO-Net experts for training and networking. 
 N° topic title aim expected impact 
Tr
ai
n
in
g 
an
d
 N
e
tw
o
rk
in
g 
 
11 Training for 
translational 
research on 
HIV/TB 
In order to bridge the gaps between HIV 
and TB communities in the EU and the 
different high-burden regions, a 
comprehensive modular training approach 
is needed, targeted at clinicians, public 
health practitioners, researchers (incl. 
social researchers), patient community, 
policy makers, laboratory personnel, civil 
society groups, the media, and others. 
The modules should be developed using 
established means including task analysis, 
training needs, etc in order to be able to 
address the different needs of the target 
groups mentioned above, and should be 
easily applicable in different target regions. 
Commonly agreed guidelines, 
identification of best practices in 
HIV and TB management and 
prevention in different sites & 
settings, improvement of 
management of HIV/TB co-
infected patients, improved 
planning, implementation, and 
monitoring and evaluation of 
HIV/TB co-infection 
programmes, and creation of a 
common base for enhanced 
collaborative research efforts. 
12 European TB 
Network of 
Excellence  
Integrate and synergize ongoing TB 
initiatives in Europe and help create a 
durable joint structure to promote stronger 
institutional integration between core 
partners of the network, with the aim of 
structuring and strengthening the 
European Research Area in the field. 
Integrate and synergize ongoing 
TB initiatives in Europe and help 
create a durable joint structure 
to promote stronger institutional 
integration between core 
partners of the network, with 
the aim of structuring and 
strengthening the European 
Research Area in the field. 
13 Global HIV/TB 
network  
Provide long-term sustainable interaction 
and coordination of efforts addressing 
HIV/TB co-infection. This will be achieved 
by detailed mapping of current networks of 
HIV, TB, and HIV/TB co-infection (what is 
there, what is lacking, how to synergize 
existing initiatives). Activities should 
include the establishment of a joint 
repository of knowledge, the creation of 
decision making models to aid national 
policy makers, the promotion of TB 
Infection control measures for HIV and TB 
infections, monitoring the implementation 
of existing HIV and TB guidelines, the 
implementation of a guideline quality 
control system, and assurance of fast 
integration of new developments into 
existing guidelines.   
Integrate HIV and TB research in 
Europe, and connect the EU 
scientific community with all 
major endemic regions as well as 
leading global initiatives. It will 
build capacities and create a 
common knowledge base for 
coordinated action. A wide 
range of stakeholders, including 
especially patient organisations, 
should be represented 
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3.5 HIV/AIDS, TB, and co-infection in the global funding portfolio: distribution and 
trends 
As a basis for the suggestion of future funding priorities in TB and HIV/MTB co-infection 
research, the current funding situation was analyzed, both on a global scale as well as 
specifically from a European perspective. 
3.5.1 Global funding for HIV/AIDS & for TB research 
The G-FINDER analysis of the latest available data on global R&D funding for HIV/AIDS 
(Figure 18) showed that by far the biggest share was going into vaccines research (65%), 
followed by microbicides (18%) and basic research (17%). Only 1% was dedicated to 
diagnostics research.  
 
 
 
 
Figure 18. G-FINDER, HIV/AIDS funding 2007. 
With regard to global TB funding, both analyses (G-FINDER and TAG, Figure 19) showed the 
majority of funding going to drugs (35% and 36%, respectively), with 21% and 22% going to 
vaccines, and 9%/10% supporting diagnostics research. In the G-FINDER report, drug 
research was closely followed by basic research with 32%, which was sub-divided into basic 
and operational research in the TAG report, receiving 20% and 7% respectively. 
 
Figure 19. G-FINDER (A) and TAG (B) TB funding 2007. 
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3.5.2 HIV/AIDS and TB funding within FP7 
As opposed to the allocation of global funding between different areas of research, the 
allocation of TB funding in FP6 and FP7 projects at the time of developing the Roadmap 
topics, as documented in the TAG reports 2005 – 2008, was clearly focusing on vaccines 
research, which received 42% of the total EU funding, followed by basic research (17%), 
drugs (16%), clinical research and epidemiology (13%) and diagnostics (12%) (Figure 20). 
 
 
 
 
Figure 20. EU FP6/FP7 TB funding. 
A graphical presentation of TB funding disbursement to the different disciplines in FP6 and 
FP7 over time shows that in the following years, the annual funding disbursements for 
vaccines research remained relatively stable, while funding for other fields increased. 
Vaccines research was temporarily surpassed by basic science research, which fell down to 
third rank again after vaccines and drug discovery more recently (Figure 21). 
 
Figure 21. TAG: FP6/FP7 TB funding disbursement since 2005. 
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In May 2012, the EC had initiated funding for 25 projects that were dealing with either 
HIV/AIDS or TB alone (12 HIV/AIDS projects and 13 TB projects) under FP7. In addition, two 
projects were explicitly focusing on HIV/MTB co-infection issues. Based on information 
extracted from these projects, the calculated average monthly funding under FP7 for both 
diseases has been constantly increasing until April 2010, with average monthly TB research 
funding surpassing monthly AIDS research funding between September 2008 and February 
2010. Since June 2010, funding for both has been falling again (Figure 22). 
 
Figure 22. HIV/AIDS funding in FP7, excluding the HEALTH 2012 & 2013 calls (for which project contracts 
are not concluded yet). 
However, the HEALTH-2012 call included several topics on infectious diseases research, and 
contract negotiations with the EC are currently ongoing, with new projects starting in late 
2012 or early 2013. While ‘HIV/AIDS, TB and Malaria’ was closed in the HEALTH-2013 call, 
several topics offered the opportunity to include research on one or both of the diseases, 
e.g. ‘HEALTH.2013.2.3.1-1: Drugs and vaccines for infections that have developed or are at 
the risk of developing significant anti-microbial resistance’. Thus, new funding is expected to 
go into HIV/AIDS and TB research from the last two HEALTH calls in FP7, while the exact 
amount cannot be estimated at the moment. 
Of the total cumulative funding allocated to HIV/AIDS and TB projects to date, 82,234,186 
EUR (62%) were invested in HIV/AIDS projects, while a maximum of 49,626,400 EUR (38%) 
EC contribution was allocated to TB projects, as shown in Figure 23. 
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Figure 23. Cumulative HIV/AIDS & TB funding in FP7 up to 2012 HEALTH call. 
The last characteristic that was systematically assessed for all FP7 projects to date was the 
distribution of partner countries, i.e. the countries in which the participating partner 
institutions are located. Figure 24 illustrates that of all countries, Germany, Italy and UK 
were most actively participating in TB projects. The most frequent EU partner countries 
involved in HIV/AIDS projects are Italy and France, followed by Germany, UK and 
Switzerland. Among countries with high TB prevalence, India, South Africa, Romania and 
Russia were involved in two or more projects. 
 
 
 
 
 
 
 
Figure 24. Countries involved in a minimum of 2 FP7 AIDS and/or TB projects, from left to right in 
descending order of number of TB projects. 
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3.6 Outreach 
To increase public understanding of the severity and complexity of HIV/MTB co-infection and 
to support advocacy for dedicated and increased funding, a short film was produced and 
widely distributed among relevant stakeholders.  
To communicate the complex immunological basics of HIV/MTB co-infection to the 
nonscientist public, the essence of the current available knowledge was distilled and 
translated into a comic strip (Figure 25 and Figure 26). The animated sequence starts with 
MTB infection, explains the mechanisms of the acquired immune response, and displays the 
formation of a granuloma as an effective means to keep the infection under control. HIV 
particles are shown as they attack the cells that are responsible for control of MTB, which 
leads to the disintegration of the granuloma and subsequently to the development of active 
TB and further spread of MTB. 
 
 
 
 
 
 
Figure 25. Animated presentation for the animation company: Macrophage activation and formation of 
the granuloma. 
 
 
 
 
 
 
Figure 26. Animated presentation for the animation company: Effect of HIV infection on control of LTBI. 
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In addition to the basic information on immunological mechanisms of interaction between 
HIV and MTB and consequences for the infected host organism, the film shows patients 
affected by the two diseases, and portrays caregivers in a South African community clinic 
(Figure 27). HIV/AIDS and TB scientists from different high burden areas explain why 
particular challenges that require further research (Figure 28), and the EUCO-Net kickoff 
meeting in Brussels is shown as a starting point of the global EC-funded initiative (Figure 29). 
         
Figure 27. A patient telling how the disease is affecting her life (left). Sister Susan van Zyl, taking care of a 
patient in the Uitsig Community Clinic (right). 
        
Figure 28. AIDS expert M. Morgado, Brazil, and TB expert G. Walzl, South Africa, explaining challenges of 
HIV/MTB co-infection and outlining research questions that need to be addressed. 
       
Figure 29. HIV/AIDS and TB scientists from around the world coming together in Brussels, to initiate the 
‘European Network for global cooperation in the field of AIDS & TB’ (EUCO-Net). 
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The film was first presented at the Stellenbosch workshop in June 2009 and has been widely 
disseminated via public television, online, and in the form of hardcopies which were 
distributed to all workshop participants, as well as to selected scientists, politicians, EC 
representatives and other stakeholders at meetings, workshops, and scientific conferences. 
Parts of the documentary were shown in the science programme "Nano" of the German 
public television channels ZDF & 3sat on World TB Day on March 24, 2009, accompanied by 
additional online articles and statistics about HIV/MTB co-infection. In May 2011, the film 
was presented in the framework of the science awareness event ‘Lange Nacht der 
Wissenschaften’ (‘science night’) at the medical campus of Saarland University. 
Online dissemination started in November 2009 through several platforms. The film was 
placed on the public website of the EUCO-Net project (http://www.euco-net.eu) and 
published by the online service AlphaGalileo (http://www.alphagalileo.org), an EU online 
service for news releases and other information from science, health, technology, the arts, 
humanities, social sciences and business. Furthermore, the film was made available via the 
science video channel AthenaWeb (http://www.athenaweb.org), a video portal and 
audiovisual workstation comparable to YouTube, specifically directed towards science 
audiovisual professionals. 
School children and university students were reached through presentations in seminars 
and workshops which included 
 June 2009: Barcelona, Universitat Pompeu Fabra, Spain 
 November 2009: Kopernikus Gymnasium Bargteheide, Germany 
 June 2010: Gesamtschule Nohfelden-Türkismühle, Germany 
Furthermore, the short film has been shown to policy makers and programme 
representatives, e.g. of the regional Ministry for Science and economics (Saarland 
Ministerium für Wissenschaft und Wirtschaft), the International Bureau of the German 
Ministry for Science and Education (BMBF), the German Science Foundation (DFG), or the 
Health Directorate of the European Commission. 
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4 Discussion 
4.1 Epidemiological data 
A comprehensive overview of the TB epidemiology (including MDR/XDR-TB) and HIV/MTB 
co-infection in all 27 EU member states was compiled as one of the elements to form a 
sound basis for the recommendation of priority issues for future research in Europe. 
As a descriptive synthesis of disease surveillance data and epidemiological estimates that 
were published in part by the ECDC (EUROPEAN CENTRE FOR DISEASE PREVENTION AND 
CONTROL, 2010b), or that are accessible through the ‘WHO's global TB database’ (WORLD 
HEALTH ORGANIZATION, 2012b), it brings added value by providing a complete picture of 
the entire EU27 and presenting a detailed dataset for each of the 27 countries. 
The following key messages could be derived from this compilation: 
 TB surveillance data (including MDR/XDR-TB) in Europe are incomplete, illustrating 
serious shortfalls of the current disease surveillance system. 
 HIV/MTB co-infection data are particularly scarce, so that conclusions could only be 
drawn from WHO estimates, which have to be interpreted with caution. 
 The full set of TB epidemiological data compiled for this thesis reveals a diverse 
distribution pattern throughout Europe, with some Eastern European countries but 
also Spain, Portugal, and Austria ranking among the top five for one or more of the 
characteristics included in the overview. 
Firstly, the collection of available data showed that even basic TB surveillance data are 
incomplete (GIEHL et al., 2011). The full set of information that is needed to calculate 
prevalence, incidence and mortality (i.e. ‘total TB cases at the time of data entry’, ‘new TB 
cases during year of reference’, and ‘TB-related deaths during the year of reference’) were 
available for 22 of the 27 countries (81.5%). MDR-TB cases were reported by 26/27 (96.3%) 
of the EU countries, but data on XDR-TB were available for 11/27 countries (40.7%) only. 
However, recent years have been characterized by a clear progress in TB monitoring in 
Europe. The ‘Framework Action Plan to Fight TB in the European Union’ (EUROPEAN CENTRE 
FOR DISEASE PREVENTION AND CONTROL, 2008) which was launched by the ECDC in 2008 
made surveillance one of the eight strategic focus areas, and has paved the way to the 
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systematic monitoring of epidemiological and core operational indicators starting this year, 
in 2012, to be presented in annual TB surveillance and monitoring reports for Europe in the 
future (SANDGREN et al., 2012). 
Secondly, the data set clearly illustrates that HIV/MTB co-infection surveillance represents a 
particular challenge, with many countries in Europe facing difficulties in collecting basic data 
on HIV/MTB co-infection (GIEHL et al., 2011). For the reference year 2008 for which the 
overview presented in this thesis has been compiled, co-infection data were available only 
for 14 of the 27 EU member states (51.9%). Again, the situation has since improved. A 2011 
systematic review identified data on HIV co-infection among TB patients for 23 out of the 30 
EU/EEA countries (76.7%) (PIMPIN et al., 2011), and a study assessing current practices in 
EU/EEA countries for monitoring HIV co-infection in TB surveillance systems, countries’ 
current co-infection burden and associated clinical practice in the same year reported that 
the HIV status of patients was collected by TB surveillance systems in 18 out of 25, i.e. 72% 
of the countries that responded to the survey (KRUIJSHAAR et al., 2011). However, assessing 
the prevalence of HIV co-infection among TB cases even today is still compromised by 
suboptimal reporting in several countries, including within the European Union (PONTALI et 
al., 2011; ABUBAKAR et al., 2012), and five years after international recording and reporting 
guidelines were updated to include HIV status in TB registers and reports, many countries 
with paper-based systems are still unable to accurately report on treatment outcomes 
disaggregated by HIV status (WORLD HEALTH ORGANIZATION, 2011b). Of those countries that 
do report data on the association between HIV infection and TB, quality and completeness 
vary greatly, mainly due to differences in testing policies and data collection (EUROPEAN 
CENTRE FOR DISEASE PREVENTION AND CONTROL, 2010a), so that data have to be read and 
interpreted carefully.  
Thirdly, based on the compiled set of information it can be concluded that TB epidemiology 
in Europe follows a diverse distribution pattern. In the reference year 2008, Romania was 
burdened by the highest prevalence and incidence, followed by Lithuania, Latvia, Bulgaria, 
Estonia, Portugal and Poland, all reporting >20 TB cases per 100,000 population (GIEHL et al., 
2011). Thus, 7 of the 27 countries (25.9%) can be characterized as intermediate-to-high 
burden countries. Many but not all of these high prevalence countries lie in Eastern Europe. 
On the other hand, among the 20 EU countries (74.1%) that belong to the group of low TB-
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prevalence countries (i.e. TB cases < 20 per 100,000), 6 countries had a prevalence of below 
6 per 100,000. With regards to TB mortality, Austria ranked number four in Europe. The 
distribution of MDR-TB followed a similar pattern: While 4/5 (80%) of the countries with the 
highest MDR prevalence were Eastern European countries, Austria again ranked number five 
in Europe. When it comes to HIV/MTB co-infection, Spain and Portugal revealed a very high 
burden as compared to other European countries. 507 of the 1,402 total HIV/MTB co-
infection cases (36.2%) in Europe were reported from Spain, while Portugal was leading in 
prevalence. These data confirm that 27 EU Member States are heterogeneous in terms of TB 
burden and characteristics of TB epidemiology, and that a reduction to ‘WHO Europe Region’ 
as applied by most epidemiology and surveillance reports up to that time is oversimplistic. 
Detailed reports specifically focusing on the TB epidemiology within Europe, as announced 
by the ECDC, will clearly facilitate informed decision-making in the future. 
When interpreting the collected data, the following limitations need to be taken into 
account: 
To deliver an overview that covers the countries and characteristics to be assessed in the 
most complete possible manner, data from two different sources and to a very limited 
extent from different reference years were combined. Data retrieved from different 
sources were routinely cross checked for consistency where values were included in both 
sources. As consistency was given in 100% of these cases, however, the combination of data 
seems appropriate. Data from different reference years are only indicated if no data for the 
standard reference year were available. In those cases, data indicated are clearly marked 
and correspond to the numbers for the closest available reference year. 
Theoretically, data from TB surveillance systems that are linked to health systems of high 
coverage and performance may capture all (or almost all) TB cases, but so far no nationwide 
survey of TB incidence has been undertaken in any country (WORLD HEALTH 
ORGANIZATION, 2011b). In all surveillance data collections, patients are routinely ‘missed’ 
because i) they do not have physical or financial access to health care, ii) they seek care, but 
TB is not diagnosed, or iii) TB is diagnosed, but the case is not reported. Only reported cases 
are documented in TB surveillance reports. Thus, differences in reported case numbers do 
not necessarily only reflect differences in actual disease burden, but are strongly dependent 
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on the surveillance system in place in the respective country. This needs to be carefully 
taken into account when interpreting reported case numbers. 
While the comparison of reported case numbers and WHO estimates revealed no striking 
differences with regards to overall TB prevalence or MDR-TB prevalence and incidence, the 
very low number of countries that reported case numbers of HIV/MTB co-infection 
represented such a clear limitation of the surveillance data collection that the overview was 
complemented by estimates for HIB/MTB co-infection. 
According to these estimates, the highest burden of HIV/MTB co-infection lies in Southern 
Europe, with Spain bearing the highest case number, and Portugal and Austria leading in 
disease prevalence. 
To assess the exactness of the available HIV/MTB co-infection surveillance data, the 
deviation between the number of reported cases and the value of the estimate was 
calculated. The comparison of actual surveillance data with given estimates is a useful 
indicator for the reliability of the reported case numbers (WORLD HEALTH ORGANIZATION, 
2012a) and clearly illustrated that the reported case numbers need to be interpreted with 
caution, if at all. While Spain ranked number one in reported cases (507), the WHO estimate 
lies at 990 cases, thus nearly doubling the reported case number. The largest deviation 
between surveillance value and estimate is shown for Romania, with the estimated case 
number exceeding the reported case number of HIV/MTB co-infected patients by more than 
200% (202 reported vs. 630 estimated cases). For the Czech Republic, on the contrary, the 
estimated case number lies more than 20% below the reported number. These examples 
illustrate that WHO estimates need to be interpreted with caution, and improvements in 
the surveillance system are urgently needed to deliver reliable information on the 
epidemiology HIV/MTB co-infection. 
In conclusion, Europe is characterized by a diverse distribution pattern of TB epidemiology, 
with high and low burden countries, and different regional hotspots. Detailed and specific 
surveillance data are thus an important basis for informed decision making, both with 
regards to guideline development as well as to the development of research concepts. 
HIV/MTB co-infection data are particularly scarce, but monitoring efforts are clearly 
increasing. Thus, surveillance reports are significantly improving, both with regards to 
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reliability and completeness of data as well to the degree of detail and specific information 
presented on the 27 European Member States.  
4.2 Diagnostics 
In a systematic review and meta-analysis of published literature, evidence for the use of the 
commercially available IGRAs (T-SPOT.TB and QFT-GIT) and TST for diagnosing active disease 
was collected and analyzed (SESTER et al., 2011). Sensitivity and specificity for active TB was 
analysed in individuals with active TB and TB suspects with other diagnoses than TB, 
respectively. This represents a new approach of analysis as compared to previous studies 
that have used low-risk individuals as specificity controls (PAI, O'BRIEN, 2008; MORI, 2009; 
DIEL et al., 2010). Moreover, it adds a new element as compared to all previous studies by 
including IGRA performance in extrasanguinous fluids. 
Three important messages could be derived from this analysis.  
 Although the sensitivity of both IGRAs was higher than that of TST for the diagnosis of 
active TB, it was not high enough to recommend the use these assays as a single rule 
out test for TB. 
 The specificity of IGRAs for the diagnosis of TB is much lower than previously reported 
(RICHELDI, 2006; PAI, O'BRIEN, 2008; MORI, 2009; DIEL et al., 2010) and inadequate to 
distinguish active TB from LTBI. 
 Data suggest that the application of the T-SPOT.TB assay to extrasanguinous fluids is 
currently the best available immunodiagnostic method for the diagnosis of active TB. 
In line with previous analyses, the sensitivity of both IGRAs for the diagnosis of active 
tuberculosis was higher than that of TST, with no difference of overall sensitivity between T-
SPOT.TB and QFT-GIT. In general, however, the diagnostic sensitivity of IGRAs is too low to 
support their use as a rule-out test for TB, as the negative predictive value would not be 
sufficiently high (SESTER et al., 2011). 
Pooled specificities of T-SPOT.TB, QFT-GIT and TST were as low as 59%, 79%, and 75%, 
respectively. Previous reports on the specificity of IGRAs for the diagnosis of tuberculosis 
that have exclusively used control groups with a low risk of MTB infection (PAI, O'BRIEN, 
2008; MORI, 2009; DIEL et al., 2010), while this analysis included a study population which is 
much more similar to patients that would be tested in a routine clinical setting in Europe. 
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The lower specificity retrieved from the meta-analysis as compared to previous studies is 
owed to the fact that many of the individuals included here have positive IGRA or TST 
results, compatible with a diagnosis of LTBI. As this realistically reflects the actual situation in 
the setting where the tests are to be used, the low specificity obtained in this analysis 
emphasizes that no commercially available immunodiagnostic test is suitable to distinguish 
active TB from LTBI in clinical practice when using peripheral blood (SESTER et al., 2011). 
The situation is different in extrasanguinous samples, where the pooled sensitivity was 
significantly higher for T-SPOT.TB (88%) compared to QFT-GIT (48%). In addition, the 
specificity of T-SPOT.TB in extrasanguinous samples was higher compared to that recorded 
in blood (82% vs. 59%), whereas specificity of QFT-GIT did not differ in the two 
compartments (79% vs. 82%). The median proportion of indeterminate results with T-
SPOT.TB was similar in blood and extrasanguinous fluids, whereas QFT-GIT had more 
indeterminate results in extrasanguinous fluids. Thus, both the higher sensitivity and the 
lower proportion of indeterminate results indicate superiority of the T-SPOT.TB when 
analyzing extrasanguinous samples from patients with active TB (SESTER et al., 2011). 
The urgent need for alternative diagnostic assays is emphasized by the fact that more than 
50% of pulmonary TB cases have undetectable AFB in sputum smear examinations. While 
neither TST nor IGRAs are clinically relevant in AFB sputum smear-positive cases, a rapid TB 
case-detection must become possible in AFB sputum smear-negative patients as well, 
especially as more than 10% of secondary TB cases are contracted from persons with 
negative AFB sputum smears (TOSTMANN et al., 2008). In this situation, the T-SPOT.TB 
assay, applied directly on extrasanguinous fluids, could be an important improvement for a 
rapid decision to initiate anti-TB treatment in countries of low TB incidence. In such low-
incidence settings, the required specimens are routinely collected in TB suspects with AFB 
sputum smear-negative TB, and the ELISPOT technology is available (LANGE, MORI, 2010). 
One of the limitations of the meta-analysis lies in the considerable heterogeneity between 
studies. Furthermore, the number of studies including children was very limited. While 
immunocompromized patients were included in many of the studies, results were not 
reported in a stratified way which would allow the specific assessment of the effect of 
immunodeficiency on test accuracy. Thus, more studies are needed including paediatric 
patients as well as allowing a stratified analysis of the effect of immunosuppression. 
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In conclusion, the evidence collected shows that IGRAs have limited accuracy in diagnosing 
active TB. While the sensitivity of IGRAs performed on blood is higher than that of TST in 
patients with active TB, the low specificity illustrates a limited value of IGRAs to distinguish 
between latently infected individuals from patients with active disease. Conversely, as 
diagnostic accuracy is high when using T-SPOT.TB on extrasanguinous fluids, T-SPOT.TB is 
currently the best available immunological method to distinguish active TB from LTBI. 
However, the number of patients analysed so far is low, evaluation is relied on pooled data, 
and the application of IGRAs on extrasanguinous fluids for the diagnosis of active TB has not 
yet been evaluated by the regulatory authorities. Thus, definite evidence for the use of 
IGRAs from samples other than blood will require more, independent, and carefully designed 
prospective studies (SESTER et al., 2011). 
The relevance of these results is emphasized by the fact that they have immediately been 
taken up in European guidelines (EUROPEAN CENTRE FOR DISEASE PREVENTION AND 
CONTROL, 2011) which state that i) IGRAs should not replace the existing standard 
diagnostic methods for the diagnosis of active TB, ii) a negative IGRA result does not exclude 
active TB disease, iii) as to the diagnosis of LTBI, IGRAs may be used in conjunction with an 
overall risk assessment in order to identify individuals for whom preventive treatment 
should be considered. 
However, the inclusion of IGRAs in diagnostic guidelines on LTBI seems useful and 
reasonable only for Europe, where their use is current practice in many countries already, 
and where availability is not a limiting factor. Collected feedback from the performed survey 
on diagnostic standards and availability of tests shows that generally, a large variety of 
assays is available and routinely used in many EU countries, but not yet common practice in 
all. However, the abovementioned ECDC guidelines which have been in place since 2011 may 
help to further harmonize diagnostic standards in Europe. In resource-poor settings, the 
situation is completely different. While IGRAs were known in all countries included in the 
survey, they were used for research purposes only, and not at all part of clinical practice, 
neither for TB diagnostics in the clinic nor for contact tracing. This may in part be due to 
insufficient awareness, but is probably most likely caused by the limitation of resources. As 
compared to the TST, IGRAs have higher resource demands as they require laboratory 
access, trained personal, implementation of quality-assured procedures, and guaranteed 
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continuous access to reagents (EUROPEAN CENTRE FOR DISEASE PREVENTION AND 
CONTROL, 2011), which is just one of many challenges in high burden areas. Furthermore, 
the high prevalence of MTB in these settings would negatively impact sensitivity even 
further, to a point where IGRAs are not at all superior to the TST anymore, which is a second 
reason why their use cannot be recommended in international guidelines. 
4.3 Funding 
As a basis for the suggestion of future funding priorities in TB and HIV/MTB co-infection 
research, an overview of the global funding situation was compiled, and a detailed analysis 
of EU FP7 funding for HIV/AIDS and TB projects was performed. This should help to avoid 
duplication of efforts and maximize the impact of research funding. 
The following observations drawn from this analysis were to be taken into account when 
formulating topic suggestions for future funding through the EU Framework Programmes: 
 Global funding for HIV/AIDS strongly focuses on vaccine development, while the main 
share of TB research funding is invested in drug development. 
 EU funding for HIV/AIDS and TB research was relatively balanced during the first half of 
FP7 and has only recently seen a relative increase of HIV/AIDS funding, while global 
R&D investment is strongly skewed towards HIV/AIDS. 
 EU-funded TB projects have recently seen a significant decrease of funding 
disbursement for diagnostics and basic sciences. 
 High burden countries are underrepresented in EU FP7 HIV/AIDS and TB projects. 
The G-FINDER analysis showed that the biggest share of global HIV/AIDS funding was 
invested in vaccines research (65% of total HIV/AIDS funding), and both the G-FINDER and 
TAG reports confirmed that the majority of TB research funding was going to drug 
development (35% and 36%, respectively), followed by vaccines (21% and 22%), with only 
9%/10% going to diagnostics research (GIEHL, 2011). This order fully reflects the R&D needs 
listed in the second Global Plan to Stop TB (RAVIGLIONE, 2006). Other important research 
areas for which funding is tracked specifically in the TAG report such as basic science or for 
operational research are not even mentioned in the Plan but their increasing importance has 
been emphasized (CHAISSON, HARRINGTON, 2009). 
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The most significant limitation of the data presented in large monitoring reports such as the 
ones provided by TAG and G-FINDER is survey non-completion. While the information 
provided by the main public funding agencies is considered to be nearly complete, private 
sector figures are described as under-reported due to non-participation of institutions, or 
provision of incomplete data. As an example, only 28 of a total of 150 SMEs (18.7%) that 
were identified to have neglected disease R&D activity provided data for the G-FINDER 
survey (MORAN et al., 2009a). Among those institutions which did report data, incorrect 
data entry or accidental omission of some grants is considered likely, though the impact of 
such mistakes is assumed to be minor. Also, the disaggregation of multi-disease grants in 
some cases may be difficult or impossible. Lastly, both monitoring reports include funding 
from e.g. the Global Fund, which is not really a research funding programme, but rather 
supports public health interventions. For all these reasons, figures indicated in the two 
monitoring reports need to be interpreted with caution, but still represent a valid and useful 
orientation with regards to global funding allocation to HIV/AIDS and TB research. 
Global research spending is strongly skewed towards HIV/AIDS: While the annual number 
of deaths from TB and AIDS are very similar, the sizes of research budgets are 
disproportionate (HARRINGTON, 2010), with total reported HIV/AIDS funding amounting to 
836.3 mio EUR as compared to 317.0 mio EUR dedicated to TB research according to the G-
FINDER 2008 report (73% and 27%, respectively, of the total funding going into HIV/AIDS and 
TB research). As opposed to these global R&D investments, funding in the ongoing 
European Framework Programme is more balanced, with 12/25 funded research projects 
(48%) focusing on HIV/AIDS, and 13/25 projects (52%) dealing with TB research in May 2012, 
receiving a total cumulative funding of 82.2 mio EUR and 49.6 mio EUR (62% and 38%), 
respectively. 
With regards to project participation, it is evident that high burden countries are 
underrepresented in EU FP7 HIV/AIDS and TB projects. Collaborative projects in FP6 and 
the first half of FP7 focused primarily on preclinical research, with very few phase I clinical 
trials, only some basic research, but increasing industrial development. The second half of 
FP7 has seen a strong increase in projects with clinical trials components, especially a large 
number of phase II clinical trials having started. As these phase II clinical trials have been 
introduced only recently, most of the projects submitted to the respective calls and selected 
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for funding are not under contract yet. Thus, participation of high prevalence countries is 
expected to clearly rise in the coming years. 
In conclusion, particularly the detailed analysis of the funding portfolio of HIV/AIDS and TB 
research within FP7 allowed to develop topic suggestions which were complementary to 
ongoing initiatives and which would be able to fill identified funding gaps, such as the recent 
significant decrease of funding disbursement for diagnostics and basic sciences. 
4.4 Research priorities 
In the framework of the EUCO-Net project and building on a baseline assessment of the 
epidemiological situation as well as current funding portfolio, priority issues for future 
research in the field of HIV/MTB co-infection were discussed and defined jointly in an 
international and intersectoral approach (SESTER et al., 2010). The project has been funded 
by the Health Directorate of the European Commission and aimed to complement the 
results of the ‘Challenges for the Future’ conference on poverty-related diseases which was 
held in Brussels on Nov 13-14 2008 to develop views on how to focus PRD research under 
the new FP7 (GRYSEELS et al., 2009). Outcomes were published in the EUCO-Net Roadmap 
to help guide and stimulate funding. While several attempts to set priorities or define focus 
areas have been described for TB research in general, none of those specifically focused on 
HIV/MTB co-infection (RYLANCE et al., 2010). 
The following main conclusions were drawn from this process: 
 Interdisciplinary and intersectoral collaboration provide a clear added value. 
 Basic sciences, clinical trials and diagnostics are key issues that need further funding. 
 HIV/MTB co-infection requires dedicated platforms. 
A unique characteristic of the EUCO-Net approach was its highly international, 
interdisciplinary and intersectoral design, and the inclusion of affected patients, which led to 
particularly fruitful discussions and useful exchange and broadening of knowledge, and 
resulted in a list of priority issues spanning the whole continuum from fundamental science 
to clinical research. 
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Four focus areas emerged from this process: basic sciences (two topic suggestions), clinical 
sciences (four topic suggestions), diagnostics (four topic suggestions), and training and 
networking (three topic suggestions). 
Suggested basic science focus topics include research to elucidate MTB pathogenesis in HIV 
infected individuals through the identification of microbial virulence and host factors, and 
the development of a personalized treatment approach for co-infected patients based on 
drug resistance and therapeutic drug monitoring (ALVAREZ et al., 2011). 
Clinical research priorities brought forward by the EUCO-Net experts include specific cohort 
studies to develop and assess TB control activities in HIV-positive individuals, and a multi-
center clinical trial network on HIV/MTB co-infection to improve treatment and prevention 
of TB in HIV-positive individuals. Furthermore, it was suggested to elucidate the 
pharmacokinetics of antiretroviral and anti-MTB drugs in relation to clinical and 
pharmacogenomic characteristics in children with HIV/MTB co-infection, and to dedicate 
efforts to the prevention of early TB-related mortality in HIV-positive individuals initiating 
ART in geographic regions of high TB-incidence (ALVAREZ et al., 2011). 
Furthermore, specific suggestions were formulated for research into improved TB diagnosis 
of in HIV-infected patients, both for active disease as well as for LTBI. Likewise, diagnosis of 
drug resistance in HIV-infected patients has been highlighted as a problem, and it has been 
recommended to fund activities that are specifically dedicated to improve diagnosis of active 
TB in HIV-positive children (ALVAREZ et al., 2011). 
All experts agreed that in addition to the abovementioned research activities, 
complementary initiatives would be needed that provide training for translational research 
on HIV/MTB co-infection. A pan-European Network of Excellence for TB has been suggested 
as highly beneficial to widely diffuse knowledge and to harmonize efforts and research 
approaches throughout Europe, taking into account the diverse situation that the EU27 is 
confronted with. And lastly, the creation of sustainable global network specifically dedicated 
to HIV/MTB co-infection has been recommended (ALVAREZ et al., 2011). 
These topics listed in the EUCO-Net Roadmap are published in (ALVAREZ et al., 2011), in line 
with the priorities identified in other initiatives described in the literature (CHURCHYARD et 
al., 2007; HESSELING et al., 2007; MARAIS et al., 2010; RYLANCE et al., 2010), and represent 
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an added value by providing detailed justifications and explicit descriptions of the expected 
impact and societal benefits that the recommended measures would bring about. In addition 
to scientific research questions that need to be addressed and concrete suggestions as to 
how these issues could be tackled, the group agreed that sustainable platforms for specific 
training and networking in the area of HIV/MTB co-infection would be needed, both 
specifically within Europe as well as in the form of a global initiative. 
Appropriateness of selected method of defining research priorities: Several possible 
methods for the identification of focus areas are described in the literature, with consensus 
statements derived from expert group discussions being the most common approach. 
Although there are formal methods for prioritizing research, a systematic review evaluating 
33 research agendas for tuberculosis published between 1998 and 2010 has shown that only 
few of the consensus groups used such methods (RYLANCE et al., 2010). Group discussion 
methods tend to provide large comprehensive lists of questions without prioritization and 
thus follow a similar approach as the EUCO-Net initiative. This approach has been described 
as useful for raising awareness and for funding in specific research domains, which were also 
the main declared goals of EUCO-Net. Furthermore, while according to the review the exact 
method used for the selection of focus topics is often not described, the process of topic 
selection and detailed description and justification of each of the priority issues has been 
clearly described for the EUCO-Net Roadmap. 
In conclusion, the EUCO-Net approach is in line with recommendations and observations 
described in the literature, both with regards to methodology for the identification of focus 
topics as well as expert group composition. In an international, interdisciplinary and 
intersectoral approach, the project delivered a Roadmap on future HIV/MTB research, 
providing concrete suggestions of initiatives to funded covering basic research, clinical 
sciences, diagnostics and training and networking. 
4.5 Outreach 
To increase public awareness and understanding of HIV/MTB co-infection, and to maximize 
the exposure of key messages, a 12-min short film was produced and disseminated to a wide 
audience, including scientists, media representatives, policy- and decision makers, and the 
public at large. 
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In addition to the generation and application of new knowledge, its communication is one of 
the main traditional roles of science (LUBCHENCO, 1998), but scientific language is 
inherently academic and thus often inefficient in delivering relevant information to 
nonscientists (CRONIN, 2010).  
To achieve these goals and to foster dialogue and debate, the EC has established an action 
plan to raise the awareness and knowledge of Europe's citizens regarding science issues 
(EUROPEAN COMMISSION, 2002) and requires FP7 project participants to communicate and 
engage with actors beyond the research community (EUROPEAN COMMISSION, 2004). 
A Eurobarometer survey on ‘Europeans, science and technology’, requested by the EC 
Research Directorate-General, showed that 60% of the general public obtains its knowledge 
of science from television, and confirms the increasing role that the internet plays in 
informing public awareness and opinion (EUROPEAN COMMISSION, 2004). Thus, the 
audiovisual format has been chosen to achieve a timely, fast and effective transmission of 
key concepts, delivering accurate information in a condensed format which is still easy to 
understand by all relevant stakeholders, including non-scientists. While the extent of 
outreach cannot really be traced, and direct impact is difficult to measure, all individuals 
involved in the direct distribution of the film have reported that it has been taken up very 
positively and recommend this format for future science communication activities. 
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5 Cooperations 
Chapter Task partner contribution partner 
institution 
contributors 
3.2.2, 4.3 Systematic 
review and 
meta-
analysis 
Selection of studies to 
be included, data 
extraction & 
interpretation 
TBNET M. Sester, C. Lange, E. 
Girardi, GB Migliori, A. 
Bossink, K. Dheda, R. Diel, 
J. Dominguez, M. Lipman, 
J. Nemeth, P. Ravn, S. 
Winkler 
3.2.2, 4.3 Systematic 
review and 
meta-
analysis 
Statistical analysis TBNET G. Sotgiu 
3.3.3 Definition of 
priority 
topics, online 
follow-up 
Programming of 
online platform 
Progressima 
s.r.l. 
A. Wagner, N. Weiler 
3.5, 4.6 Short film 
production  
Technical realization Sichtzeit 
GmbH 
T. Hillebrandt, R. Holz, D. 
Hunger, B. Wiggeshoff 
3.5, 4.6 Short film 
production 
Preparation of filming 
and local coordination 
in Cape Town 
Stellenbosch 
University; 
Desmond Tutu 
TB Centre 
A. Loxton; G. Black; 
 
S. van Zyl 
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